Literatur
- 1
Shivananda S, Lennard-Jones J, Logan R. et al .
Incidence of inflammatory bowel disease across Europe: is there a difference between
north and south? Results of the European Collaborative Study on Inflammatory Bowel
Disease (EC-IBD).
Gut.
1996;
39
690-697
- 2
Timmer A, Breuer-Katschinski B, Goebell H.
Time trends in the incidence and disease location of Crohn’s disease 1980 – 1995:
a prospective analysis in an urban population in Germany.
Inflamm Bowel Dis.
1999;
5
79-84
- 3
Vind I, Riis L, Jess T. et al .
Increasing incidences of inflammatory bowel disease and decreasing surgery rates in
Copenhagen City and County, 2003 – 2005: a population-based study from the Danish
Crohn colitis database.
Am J Gastroenterol.
2006;
101
1274-1282
- 4
Rosch M, Leidl R, Tirpitz C. et al .
Cost measurement based on a cost diary in patients with inflammatory bowel disease.
Z Gastroenterol.
2002;
40
217-228
- 5
Stange E F, Schreiber S, Folsch U R. et al .
Diagnostik und Therapie des Morbus Crohn: Ergebnisse einer evidenzbasierten Konsensuskonfrenz
der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten.
Z Gastroenterol.
2003;
41
19-20
- 6
Stange E F, Travis S P, Vermeire S. et al .
European evidence based consensus on the diagnosis and management of Crohn’s disease:
definitions and diagnosis.
Gut.
2006;
55 (Suppl 1)
i1-i15
- 7
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Ärztliche
Zentralstelle für Qualitätssicherung .
Das Leitlinien-Manual.
Z Ärztl Fortbild Qualitätssich.
2001;
95 (Suppl 1)
1-84
- 8
Hoffmann J C, Zeitz M, Bischoff S C. et al .
Diagnostik und Therapie der Colitis ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz
der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen zusammen mit
dem Kompetenznetz chronisch entzündliche Darmerkrankungen.
Z Gastroenterol.
2004;
42
979-1042
- 9 Phillips B, Ball C, Sackett D. et al .Oxford-Centre for Evidence Based Medicine
– Levels of Evidence and Grades of Recommendation. Online im WWW. URL: http://wwwcebmnet/indexaspx?o=
1025. 2001
- 10
Hyams J, Markowitz J, Otley A. et al .
Evaluation of the pediatric crohn disease activity index: a prospective multicenter
experience.
J Pediatr Gastroenterol Nutr.
2005;
41
416-421
- 11
Sandborn W J, Feagan B G, Hanauer S B. et al .
A review of activity indices and efficacy endpoints for clinical trials of medical
therapy in adults with Crohn’s disease.
Gastroenterology.
2002;
122
512-530
- 12
Lennard-Jones J E, Shivananda S.
Clinical uniformity of inflammatory bowel disease a presentation and during the first
year of disease in the north and south of Europe. EC-IBD Study Group.
Eur J Gastroenterol Hepatol.
1997;
9
353-359
- 13
Bridger S, Lee J C, Bjarnason I. et al .
In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers
tend to develop Crohn’s disease and non-smokers develop ulcerative colitis.
Gut.
2002;
51
21-25
- 14
Fine K D, Schiller L R.
AGA technical review on the evaluation and management of chronic diarrhea.
Gastroenterology.
1999;
116
1464-1486
- 15
Farmer R, Hawk W, Turnbull R.
Clinical patterns in Crohn’s disease: a statistical study of 615 cases.
Gastroenterology.
1975;
68
627-635
- 16
Szumera M, Landowski P, Kaminska B. et al .
Bone mineral density in inflammatory bowel diseases in children.
Med Wieku Rozwoj.
2006;
10
445-451
- 17
Andersson R E, Olaison G, Tysk C. et al .
Appendectomy is followed by increased risk of Crohn’s disease.
Gastroenterology.
2003;
124
40-46
- 18
IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology
and Nutrition .
Inflammatory bowel disease in children and adolescents: recommendations for diagnosis
– the Porto criteria.
J Pediatr Gastroenterol Nutr.
2005;
41
1-7
- 19
Fagan E A, Dyck R F, Maton P N. et al .
Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis.
Eur J Clin Invest.
1982;
12
351-359
- 20
Vermeire S, Van Assche G, Rutgeerts P.
C-reactive protein as a marker for inflammatory bowel disease.
Inflamm Bowel Dis.
2004;
10
661-665
- 21
Solem C A, Loftus E V, Tremaine W J. et al .
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic
activity in inflammatory bowel disease.
Inflamm Bowel Dis.
2005;
11
707-712
- 22
Mylonaki Jr M, Langmead L, Pantes A. et al .
Enteric infection in relapse of inflammatory bowel disease: importance of microbiological
examination of stool.
Eur J Gastroenterol Hepatol.
2004;
16
775-778
- 23
Korczowski B, Szybist W.
Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies.
Acta Paediatr.
2004;
93
169-173
- 24
Herrlinger K R, Dittmann R, Weitz G. et al .
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
Inflamm Bowel Dis.
2004;
10
229-233
- 25
Boirivant M, Leoni M, Tariciotti D. et al .
The clinical significance of serum C reactive protein levels in Crohn’s disease. Results
of a prospective longitudinal study.
J Clin Gastroenterol.
1988;
10
401-405
- 26
Aadland E, Fagerhol M K.
Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Eur J Gastroenterol Hepatol.
2002;
14
823-825
- 27
Roseth A G, Aadland E, Jahnsen J. et al .
Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel
granulocyte marker protein.
Digestion.
1997;
58
176-180
- 28
Roseth A G, Schmidt P N, Fagerhol M K.
Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin,
a granulocyte marker protein, in patients with inflammatory bowel disease.
Scand J Gastroenterol.
1999;
34
50-54
- 29
Fine K D, Ogunji F, George J. et al .
Utility of a rapid fecal latex agglutination test detecting the neutrophil protein,
lactoferrin, for diagnosing inflammatory causes of chronic diarrhea.
Am J Gastroenterol.
1998;
93
1300-1305
- 30
Kane S V, Sandborn W J, Rufo P A. et al .
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
Am J Gastroenterol.
2003;
98
1309-1314
- 31
Jong N S, Leach S T, Day A S.
Fecal S 100A12: a novel noninvasive marker in children with Crohn’s disease.
Inflamm Bowel Dis.
2006;
12
566-572
- 32
Kaiser de T, Langhorst J, Wittkowski H. et al .
Fecal S 100A12 as non-invasive marker distinguishing inflammatory bowel disease from
irritable bowel syndrome.
Gut.
2007;
56
1706
- 33
Roon A C, Karamountzos von L, Purkayastha S. et al .
Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal
malignancy.
Am J Gastroenterol.
2007;
102
803-813
- 34
Pascu M, Roznowski A B, Muller H P. et al .
Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging
in patients with inflammatory bowel disease of the terminal ileum and large bowel.
Inflamm Bowel Dis.
2004;
10
373-382
- 35
Parente F, Greco S, Molteni M. et al .
Role of early ultrasound in detecting inflammatory intestinal disorders and identifying
their anatomical location within the bowel.
Aliment Pharmacol Ther.
2003;
18
1009-1016
- 36
Maconi G, Sampietro G M, Parente F. et al .
Contrast radiology, computed tomography and ultrasonography in detecting internal
fistulas and intra-abdominal abscesses in Crohn’s disease: a prospective comparative
study.
Am J Gastroenterol.
2003;
98
1545-1555
- 37
Geboes K, Ectors N, D’Haens G. et al .
Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory
bowel disease?.
Am J Gastroenterol.
1998;
93
201-206
- 38
Coremans G, Rutgeerts P, Geboes K. et al .
The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn’s disease.
Gastrointest Endosc.
1984;
30
167-172
- 39
Morrin M, Raptopoulos V, Weisinger K. et al .
Virtual Colonography: Techniques and Current Clinical Applications.
Surg Technol Int.
2000;
VIII
121-127
- 40
Beall D P, Fortman B J, Lawler B C. et al .
Imaging bowel obstruction: a comparison between fast magnetic resonance imaging and
helical computed tomography.
Clin Radiol.
2002;
57
719-724
- 41
Sawczenko A, Sandhu B K.
Presenting features of inflammatory bowel disease in Great Britain and Ireland.
Arch Dis Child.
2003;
88
995-1000
- 42
Castellaneta S P, Afzal N A, Greenberg M. et al .
Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel
disease.
J Pediatr Gastroenterol Nutr.
2004;
39
257-261
- 43
Abdullah B A, Gupta S K, Croffie J M. et al .
The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory
bowel disease: a 7-year study.
J Pediatr Gastroenterol Nutr.
2002;
35
636-640
- 44
Mashako M N, Cezard J P, Navarro J. et al .
Crohn’s disease lesions in the upper gastrointestinal tract: correlation between clinical,
radiological, endoscopic, and histological features in adolescents and children.
J Pediatr Gastroenterol Nutr.
1989;
8
442-446
- 45
Elitsur Y, Blankenship P, Lawrence Z.
Propofol sedation for endoscopic procedures in children.
Endoscopy.
2000;
32
788-791
- 46
Wengrower D, Gozal D, Gozal Y. et al .
Complicated endoscopic pediatric procedures using deep sedation and general anesthesia
are safe in the endoscopy suite.
Scand J Gastroenterol.
2004;
39
283-286
- 47
Lipson A, Bartram C I, Williams C B. et al .
Barium studies and ileoscopy compared in children with suspected Crohn’s disease.
Clin Radiol.
1990;
41
5-8
- 48
Halligan S, Nicholls S, Beattie R M. et al .
The role of small bowel radiology in the diagnosis and management of Crohn’s disease.
Acta Paediatr.
1995;
84
1375-1378
- 49
Alberini J L, Badran A, Freneaux E. et al .
Technetium-99m HMPAO-labeled leukocyte imaging compared with endoscopy, ultrasonography,
and contrast radiology in children with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr.
2001;
32
278-286
- 50
Bremner A R, Pridgeon J, Fairhurst J. et al .
Ultrasound scanning may reduce the need for barium radiology in the assessment of
small-bowel Crohn’s disease.
Acta Paediatr.
2004;
93
479-481
- 51
Laghi A, Borrelli O, Paolantonio P. et al .
Contrast enhanced magnetic resonance imaging of the terminal ileum in children with
Crohn’s disease.
Gut.
2003;
52
393-397
- 52
Darbari A, Sena L, Argani P. et al .
Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing
pediatric IBD.
Inflamm Bowel Dis.
2004;
10
67-72
- 53
Schmidt T, Hohl C, Haage P. et al .
Phase-inversion tissue harmonic imaging compared to fundamental B-mode ultrasound
in the evaluation of the pathology of large and small bowel.
Eur Radiol.
2005;
15
2021-2030
- 54
Parente F, Greco S, Molteni M. et al .
Oral contrast enhanced bowel ultrasonography in the assessment of small intestine
Crohn’s disease. A prospective comparison with conventional ultrasound, × ray studies,
and ileocolonoscopy.
Gut.
2004;
53
1652-1657
- 55
Schreyer A G, Geissler A, Albrich H. et al .
Abdominal MRI after enteroclysis or with oral contrast in patients with suspected
or proven Crohn’s disease.
Clin Gastroenterol Hepatol.
2004;
2
491-497
- 56
Schreyer A G, Seitz J, Feuerbach S. et al .
Modern imaging using computer tomography and magnetic resonance imaging for inflammatory
bowel disease (IBD) AU 1.
Inflamm Bowel Dis.
2004;
10
45-54
- 57
Bernstein C N, Greenberg H, Boult I. et al .
A prospective comparison study of MRI versus small bowel follow-through in recurrent
Crohn’s disease.
Am J Gastroenterol.
2005;
100
2493-2502
- 58
Potthast S, Rieber A, Von Tirpitz C. et al .
Ultrasound and magnetic resonance imaging in Crohn’s disease: a comparison.
Eur Radiol.
2002;
12
1416-1422
- 59
Ludwig D, Wiener S, Bruning A. et al .
Mesenteric blood flow is related to disease activity and risk of relapse in Crohn’s
disease: a prospective follow-up study.
Am J Gastroenterol.
1999;
94
2942-2950
- 60
Homann N, Klarmann U, Fellermann K. et al .
Mesenteric pulsatility index analysis predicts response to azathioprine in patients
with Crohn’s disease.
Inflamm Bowel Dis.
2005;
11
126-132
- 61
Heyne R, Rickes S, Bock P. et al .
Non-invasive evaluation of activity in inflammatory bowel disease by power Doppler
sonography.
Z Gastroenterol.
2002;
40
171-175
- 62
Di Sabatino A, Fulle I, Ciccocioppo R. et al .
Doppler enhancement after intravenous levovist injection in Crohn’s disease.
Inflamm Bowel Dis.
2002;
8
251-257
- 63
Wagtmans M J, Verspaget H W, Lamers C B. et al .
Clinical aspects of Crohn’s disease of the upper gastrointestinal tract: a comparison
with distal Crohn’s disease.
Am J Gastroenterol.
1997;
92
1467-1471
- 64
Rutgeerts P, Onette E, Vantrappen G. et al .
Crohn’s disease of the stomach and duodenum: A clinical study with emphasis on the
value of endoscopy and endoscopic biopsies.
Endoscopy.
1980;
12
288-294
- 65
Albert J G, Martiny F, Krummenerl A. et al .
Diagnosis of small bowel Crohn’s disease: a prospective comparison of capsule endoscopy
with magnetic resonance imaging and fluoroscopic enteroclysis.
Gut.
2005;
54
1721-1727
- 66
Golder S K, Schreyer A G, Endlicher E. et al .
Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected
small bowel disease.
Int J Colorectal Dis.
2006;
21
97-104
- 67
Voderholzer W A, Beinhoelzl J, Rogalla P. et al .
Small bowel involvement in Crohn’s disease: a prospective comparison of wireless capsule
endoscopy and computed tomography enteroclysis.
Gut.
2005;
54
369-373
- 68
Liangpunsakul S, Chadalawada V, Rex D K. et al .
Wireless capsule endoscopy detects small bowel ulcers in patients with normal results
from state of the art enteroclysis.
Am J Gastroenterol.
2003;
98
1295-1298
- 69
Eliakim R, Fischer D, Suissa A. et al .
Wireless capsule video endoscopy is a superior diagnostic tool in comparison to barium
follow-through and computerized tomography in patients with suspected Crohn’s disease.
Eur J Gastroenterol Hepatol.
2003;
15
363-367
- 70
Triester S L, Leighton J A, Leontiadis G I. et al .
A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities
in patients with non-stricturing small bowel Crohn’s disease.
Am J Gastroenterol.
2006;
101
954-964
- 71
Graham D Y, Opekun A R, Willingham F F. et al .
Visible small-intestinal mucosal injury in chronic NSAID users.
Clin Gastroenterol Hepatol.
2005;
3
55-59
- 72
Goldstein J L, Eisen G M, Lewis B. et al .
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib,
naproxen plus omeprazole, and placebo.
Clin Gastroenterol Hepatol.
2005;
3
133-141
- 73
Oshitani N, Yukawa T, Yamagami H. et al .
Evaluation of deep small bowel involvement by double-balloon enteroscopy in Crohn’s
disease.
Am J Gastroenterol.
2006;
101
1484-1489
- 74
Geerling B J, Badart-Smook A, Stockbrugger R W. et al .
Comprehensive nutritional status in recently diagnosed patients with inflammatory
bowel disease compared with population controls.
Eur J Clin Nutr.
2000;
54
514-521
- 75
Filippi J, Al-Jaouni R, Wiroth J B. et al .
Nutritional deficiencies in patients with Crohn’s disease in remission.
Inflamm Bowel Dis.
2006;
12
185-191
- 76
Rodemann J F, Dubberke E R, Reske K A. et al .
Incidence of Clostridium difficile infection in inflammatory bowel disease.
Clin Gastroenterol Hepatol.
2007;
5
339-344
- 77
Issa M, Vijayapal A, Graham M B. et al .
Impact of Clostridium difficile on inflammatory bowel disease.
Clin Gastroenterol Hepatol.
2007;
5
345-351
- 78
Takahashi Y, Tange T.
Prevalence of cytomegalovirus infection in inflammatory bowel disease patients.
Dis Colon Rectum.
2004;
47
722-726
- 79
Dimitroulia E, Spanakis N, Konstantinidou A E. et al .
Frequent detection of cytomegalovirus in the intestine of patients with inflammatory
bowel disease.
Inflamm Bowel Dis.
2006;
12
879-884
- 80
Cottone M, Pietrosi G, Martorana G. et al .
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s
colitis.
Am J Gastroenterol.
2001;
96
773-775
- 81
Hommes D W, Sterringa G, Deventer S J. et al .
The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review
and evidence-based recommendations for future research.
Inflamm Bowel Dis.
2004;
10
245-250
- 82
Eaden J A, Abrams K R, Mayberry J F.
The risk of colorectal cancer in ulcerative colitis: a meta-analysis.
Gut.
2001;
48
526-535
- 83
Jess van T, Gamborg M, Matzen P. et al .
Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based
cohort studies.
Am J Gastroenterol.
2005;
100
2724-2729
- 84
Jess T, Loftus E V, Velayos F S. et al .
Risk of intestinal cancer in inflammatory bowel disease: a population-based study
from olmsted county, Minnesota.
Gastroenterology.
2006;
130
1039-1046
- 85
Bernstein C N, Blanchard J F, Kliewer Jr E. et al .
Cancer risk in patients with inflammatory bowel disease: a population-based study.
Cancer.
2001;
91
854-862
- 86
Hoffmann J C, Zeitz M, Bischoff S C. et al .
Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus
conference by the German society of Digestive and Metabolic Diseases and the competence
network on inflammatory bowel disease.
Z Gastroenterol.
2004;
42
979-983
- 87
Ogura Y, Bonen D K, Inohara N. et al .
A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.
Nature.
2001;
411
603-606
- 88
Hugot J P, Chamaillard M, Zouali H. et al .
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease.
Nature.
2001;
411
599-603
- 89
Ahmad T, Armuzzi A, Bunce M. et al .
The molecular classification of the clinical manifestations of Crohn’s disease.
Gastroenterology.
2002;
122
854-866
- 90
Lesage S, Zouali H, Cezard J P. et al .
CARD15 /NOD2 mutational analysis and genotype-phenotype correlation in 612 patients
with inflammatory bowel disease.
Am J Hum Genet.
2002;
70
845-857
- 91
Radlmayr M, Torok H P, Martin K. et al .
The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic
phenotypes in Crohn’s disease.
Gastroenterology.
2002;
122
2091-2092
- 92
Peeters M, Joossens S, Vermeire S. et al .
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies
in inflammatory bowel disease.
Am J Gastroenterol.
2001;
96
730-734
- 93
Zholudev A, Zurakowski D, Young W. et al .
Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with
Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease
phenotype.
Am J Gastroenterol.
2004;
99
2235-2241
- 94
Plevy S.
Do serological markers and cytokines determine the indeterminate?.
J Clin Gastroenterol.
2004;
38
S51-56
- 95
Hollander D, Vadheim C M, Brettholz E. et al .
Increased intestinal permeability in patients with Crohn’s disease and their relatives.
A possible etiologic factor.
Ann Intern Med.
1986;
105
883-885
- 96
Wyatt J, Vogelsang H, Hubl W. et al .
Intestinal permeability and the prediction of relapse in Crohn’s disease.
Lancet.
1993;
341
1437-1439
- 97
Silverberg M S, Satsangi J, Ahmad T. et al .
Toward an integrated clinical, molecular and serological classification of inflammatory
bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
Can J Gastroenterol.
2005;
19 (Suppl A)
5-36
- 98
Allison M C, Hamilton-Dutoit S J, Dhillon A P. et al .
The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory
bowel disease.
Q J Med.
1987;
65
985-995
- 99
Bentley E, Jenkins D, Campbell F. et al .
How could pathologists improve the initial diagnosis of colitis? Evidence from an
international workshop.
J Clin Pathol.
2002;
55
955-960
- 100
Dejaco C, Oesterreicher C, Angelberger S. et al .
Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis.
Endoscopy.
2003;
35
1004-1008
- 101
Dube A K, Cross S S, Lobo A J.
Audit of the histopathological diagnosis of non-neoplastic colorectal biopsies: achievable
standards for the diagnosis of inflammatory bowel disease.
J Clin Pathol.
1998;
51
378-381
- 102
Dundas S A, Dutton J, Skipworth P.
Reliability of rectal biopsy in distinguishing between chronic inflammatory bowel
disease and acute self-limiting colitis.
Histopathology.
1997;
31
60-66
- 103
Jenkins D, Balsitis M, Gallivan S. et al .
Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory
bowel disease. The British Society of Gastroenterology Initiative.
J Clin Pathol.
1997;
50
93-105
- 104
Nostrant T T, Kumar N B, Appelman H D.
Histopathology differentiates acute self-limited colitis from ulcerative colitis.
Gastroenterology.
1987;
92
318-328
- 105
Schumacher G, Kollberg B, Sandstedt B.
A prospective study of first attacks of inflammatory bowel disease and infectious
colitis. Histologic course during the 1st year after presentation.
Scand J Gastroenterol.
1994;
29
318-332
- 106
Seldenrijk C A, Morson B C, Meuwissen S G. et al .
Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory
bowel disease: diagnostic implications.
Gut.
1991;
32
1514-1520
- 107
Surawicz C M, Belic L.
Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory
bowel disease.
Gastroenterology.
1984;
86
104-113
- 108
Tanaka M, Masuda T, Yao T. et al .
Observer variation of diagnoses based on simple biopsy criteria differentiating among
Crohn’s disease, ulcerative colitis, and other forms of colitis.
J Gastroenterol Hepatol.
2001;
16
1368-1372
- 109
Tanaka M, Riddell R H, Saito H. et al .
Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory
bowel disease from other forms of colitis and of Crohn’s disease from ulcerative colitis.
Scand J Gastroenterol.
1999;
34
55-67
- 110
Tanaka M, Saito H, Fukuda S. et al .
Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis,
and other forms of colitis: measurement of validity.
Scand J Gastroenterol.
2000;
35
281-286
- 111
Theodossi A, Spiegelhalter D J, Jass J. et al .
Observer variation and discriminatory value of biopsy features in inflammatory bowel
disease.
Gut.
1994;
35
961-968
- 112
Mahadeva U, Martin J P, Patel N K. et al .
Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction
of Crohn’s disease from ulcerative colitis.
Histopathology.
2002;
41
50-55
- 113
Schmitz-Moormann P, Pittner P M, Malchow H. et al .
The granuloma in Crohn’s disease. A bioptical study.
Pathol Res Pract.
1984;
178
467-476
- 114
Cherian S, Singh P.
Is routine ileoscopy useful? An observational study of procedure times, diagnostic
yield, and learning curve.
Am J Gastroenterol.
2004;
99
2324-2329
- 115
Surawicz C M.
Serial sectioning of a portion of a rectal biopsy detects more focal abnormalities:
a prospective study of patients with inflammatory bowel disease.
Dig Dis Sci.
1982;
27
434-436
- 116
Surawicz C M, Meisel J L, Ylvisaker T. et al .
Rectal biopsy in the diagnosis of Crohn’s disease: value of multiple biopsies and
serial sectioning.
Gastroenterology.
1981;
80
66-71
- 117
Geboes K, Dalle I.
Influence of treatment on morphological features of mucosal inflammation.
Gut.
2002;
50 (Suppl 3)
III37-III42
- 118
Odze R, Antonioli D, Peppercorn M. et al .
Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology
in chronic ulcerative colitis.
Am J Surg Pathol.
1993;
17
869-875
- 119
Kleer C G, Appelman H D.
Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with
time.
Am J Surg Pathol.
1998;
22
983-989
- 120
Bousvaros A, Antonioli D A, Colletti R B. et al .
Differentiating ulcerative colitis from Crohn disease in children and young adults:
report of a working group of the North American Society for Pediatric Gastroenterology,
Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America.
J Pediatr Gastroenterol Nutr.
2007;
44
653-674
- 121
Glickman J N, Bousvaros A, Farraye F A. et al .
Pediatric patients with untreated ulcerative colitis may present initially with unusual
morphologic findings.
Am J Surg Pathol.
2004;
28
190-197
- 122
Robert M E, Tang L, Hao L M. et al .
Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences
in pediatric populations are limited to children younger than 10 years.
Am J Surg Pathol.
2004;
28
183-189
- 123 Autschbach F. Pathologie der CED. Hoffmann JC, Krösen AJ, Klump B Chronisch entzündliche
Darmerkrankungen Das CED-Handbuch für Klinik und Praxis Stuttgart; Thieme 2004: 110-122
- 124
Borchard F.
Differential diagnosis of colitis.
Verh Dtsch Ges Pathol.
1999;
83
110-121
- 125
Herbay von A.
Histopathologische Diagnostik chronischentzündlicher Darmerkrankungen. Historischer
Rückblick und aktuelle Übersicht.
Pathologe.
1999;
20
276-287
- 126
Lemberg D A, Clarkson C M, Bohane T D. et al .
Role of esophagogastroduodenoscopy in the initial assessment of children with inflammatory
bowel disease.
J Gastroenterol Hepatol.
2005;
20
1696-1700
- 127
Oberhuber G, Hirsch M, Stolte M.
High incidence of upper gastrointestinal tract involvement in Crohn’s disease.
Virchows Arch.
1998;
432
49-52
- 128
Oberhuber G, Puspok A, Oesterreicher C. et al .
Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn’s
disease.
Gastroenterology.
1997;
112
698-706
- 129
Parente F, Cucino C, Bollani S. et al .
Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence,
immunohistochemical characteristics, and diagnostic role.
Am J Gastroenterol.
2000;
95
705-711
- 130
Sharif F, McDermott M, Dillon M. et al .
Focally enhanced gastritis in children with Crohn’s disease and ulcerative colitis.
Am J Gastroenterol.
2002;
97
1415-1420
- 131
Gomes P, du Boulay C, Smith C L. et al .
Relationship between disease activity indices and colonoscopic findings in patients
with colonic inflammatory bowel disease.
Gut.
1986;
27
92-95
- 132
D’Haens G, Van Deventer S, Van Hogezand R. et al .
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies
in Crohn’s disease: A European multicenter trial.
Gastroenterology.
1999;
116
1029-1034
- 133
Riley S A, Mani V, Goodman M J. et al .
Microscopic activity in ulcerative colitis: what does it mean?.
Gut.
1991;
32
174-178
- 134
Cook M G, Dixon M F.
An analysis of the reliability of detection and diagnostic value of various pathological
features in Crohn’s disease and ulcerative colitis.
Gut.
1973;
14
255-262
- 135 Hamilton S R. Diagnosis and comparison of ulcerative colitis and Crohn’s disease
involving the colon. Norris HT Pathology of the colon, small intestine, and anus New
York; Churchill Livingstone 1991: 1-22
- 136
Price A B, Morson B C.
Inflammatory bowel disease: the surgical pathology of Crohn’s disease and ulcerative
colitis.
Hum Pathol.
1975;
6
7-29
- 137
Sheehan A L, Warren B F, Gear M W. et al .
Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice.
Br J Surg.
1992;
79
955-958
- 138
Canavan C, Abrams K R, Mayberry J.
Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease.
Aliment Pharmacol Ther.
2006;
23
1097-1104
- 139
Collins P D, Mpofu C, Watson A J. et al .
Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory
bowel disease.
Cochrane Database Syst Rev.
2006;
CD000279
- 140
Ekbom A, Helmick C, Zack M. et al .
Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement.
Lancet.
1990;
336
357-359
- 141
Maykel J A, Hagerman G, Mellgren A F. et al .
Crohn’s colitis: the incidence of dysplasia and adenocarcinoma in surgical patients.
Dis Colon Rectum.
2006;
49
950-957
- 142
Riddell R H, Goldman H, Ransohoff D F. et al .
Dysplasia in inflammatory bowel disease: standardized classification with provisional
clinical applications.
Hum Pathol.
1983;
14
931-968
- 143
Choi P M, Zelig M P.
Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications
for carcinogenesis and prevention.
Gut.
1994;
35
950-954
- 144
Svrcek M, Cosnes J, Beaugerie L. et al .
Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative
colitis.
Histopathology.
2007;
50
574-583
- 145 Hamilton S R, Vogelstein B, Kudo S. Carcinoma of the colon and rectum. Hamilton
SR, Aaltonen LA World Health Organization Classification of Tumors Pathology and Genetics
of Tumors of the Digestive System Lyon; IARC Press 2000
- 146
Schlemper R J, Riddell R H, Kato Y. et al .
The Vienna classification of gastrointestinal epithelial neoplasia.
Gut.
2000;
47
251-255
- 147
Rubin C E, Haggitt R C, Burmer G C. et al .
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative
colitis.
Gastroenterology.
1992;
103
1611-1620
- 148
Kiesslich R, Fritsch J, Holtmann M. et al .
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia
and colon cancer in ulcerative colitis.
Gastroenterology.
2003;
124
880-888
- 149
Rutter M D, Saunders B P, Schofield G. et al .
Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative
colitis.
Gut.
2004;
53
256-260
- 150
Blackstone M O, Riddell R H, Rogers B H. et al .
Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing
ulcerative colitis: an indication for colectomy.
Gastroenterology.
1981;
80
366-374
- 151
Bernstein C N, Shanahan F, Weinstein W M.
Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?.
Lancet.
1994;
343
71-74
- 152
Engelsgjerd M, Farraye F A, Odze R D.
Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic
ulcerative colitis.
Gastroenterology.
1999;
117
1288-1294; discussion 1488 – 1291
- 153
Rubin P H, Friedman S, Harpaz N. et al .
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic
resection of dysplastic polyps.
Gastroenterology.
1999;
117
1295-1300
- 154
Torres C, Antonioli D, Odze R D.
Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic,
and follow-up study of 89 polyps from 59 patients.
Am J Surg Pathol.
1998;
22
275-284
- 155
Vieth M, Behrens H, Stolte M.
Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment.
Gut.
2006;
55
1151-1155
- 156
Schneider A, Stolte M.
Differential diagnosis of adenomas and dysplastic lesions in patients with ulcerative
colitis.
Z Gastroenterol.
1993;
31
653-656
- 157
Befrits R, Ljung T, Jaramillo E. et al .
Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up
study.
Dis Colon Rectum.
2002;
45
615-620
- 158
Jess T, Loftus E V, Velayos F S. et al .
Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based
study from Olmsted County, Minnesota.
Inflamm Bowel Dis.
2006;
12
669-676
- 159
Lim C H, Dixon M F, Vail Jr A. et al .
Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.
Gut.
2003;
52
1127-1132
- 160
Ullman T, Croog V, Harpaz N. et al .
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative
colitis.
Gastroenterology.
2003;
125
1311-1319
- 161
Eaden J, Abrams K, McKay H. et al .
Inter-observer variation between general and specialist gastrointestinal pathologists
when grading dysplasia in ulcerative colitis.
J Pathol.
2001;
194
152-157
- 162
Jeejeebhoy K N, Detsky A S, Baker J P.
Assessment of nutritional status.
JPEN J Parenter Enteral Nutr.
1990;
14
193S-196S
- 163
Lochs H, Dejong C, Hammarqvist F. et al .
ESPEN Guidelines on Enteral Nutrition: Gastroenterology.
Clin Nutr.
2006;
25
260-274
- 164
Otley A, Steinhart A H.
Budesonide for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2005;
CD000296
- 165
Bar-Meir S, Chowers Y, Lavy A. et al .
Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli
Budesonide Study Group.
Gastroenterology.
1998;
115
835-840
- 166
Caesar I, Gross V, Roth M. et al .
Treatment of active and postactive ileal and colonic Crohn’s disease with oral pH-modified-release
budesonide. German Budesonide Study Group.
Hepatogastroenterology.
1997;
44
445-451
- 167
Campieri M, Ferguson A, Doe W. et al .
Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The
Global Budesonide Study Group.
Gut.
1997;
41
209-214
- 168
Escher J C.
Budesonide versus prednisolone for the treatment of active Crohn’s disease in children:
a randomized, double-blind, controlled, multicentre trial.
Eur J Gastroenterol Hepatol.
2004;
16
47-54
- 169
Greenberg G R, Feagan B G, Martin F. et al .
Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study
Group.
N Engl J Med.
1994;
331
836-841
- 170
Gross V, Andus T, Caesar I. et al .
Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s
disease. German/Austrian Budesonide Study Group.
Eur J Gastroenterol Hepatol.
1996;
8
905-909
- 171
Hanauer S B, Stromberg U.
Oral Pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind,
placebo-controlled trials.
Clin Gastroenterol Hepatol.
2004;
2
379-388
- 172
Su C.
Outcomes of placebo therapy in inflammatory bowel disease.
Inflamm Bowel Dis.
2006;
12
328-333
- 173
Prantera C, Lochs H, Campieri M. et al .
Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized,
placebo-controlled trial with rifaximin.
Aliment Pharmacol Ther.
2006;
23
1117-1125
- 174
Colombel J F, Lemann M, Cassagnou M. et al .
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active
Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives
(GETAID).
Am J Gastroenterol.
1999;
94
674-678
- 175
Goodgame R W, Kimball K, Akram S. et al .
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn’s
disease.
Aliment Pharmacol Ther.
2001;
15
1861-1866
- 176
Sutherland L, Singleton J, Sessions J. et al .
Double blind, placebo controlled trial of metronidazole in Crohn’s disease.
Gut.
1991;
32
1071-1075
- 177
Ambrose N S, Allan R N, Keighley M R. et al .
Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. A prospective
randomized study.
Dis Colon Rectum.
1985;
28
81-85
- 178
Blichfeldt P, Blomhoff J P, Myhre E. et al .
Metronidazole in Crohn’s disease. A double blind cross-over clinical trial.
Scand J Gastroenterol.
1978;
13
123-127
- 179
Arnold G L, Beaves M R, Pryjdun V O. et al .
Preliminary study of ciprofloxacin in active Crohn’s disease.
Inflamm Bowel Dis.
2002;
8
10-15
- 180
Prantera C, Zannoni F, Scribano M L. et al .
An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled
clinical trial of metronidazole plus ciprofloxacin.
Am J Gastroenterol.
1996;
91
328-332
- 181
Selby W, Pavli P, Crotty B. et al .
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine
for Crohn’s disease.
Gastroenterology.
2007;
132
2313-2319
- 182
Modigliani R, Mary J Y, Simon J F. et al .
Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution
on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives.
Gastroenterology.
1990;
98
811-818
- 183
Benchimol E, Seow C, Steinhart A. et al .
Traditional corticosteroids for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2008;
CD006792
- 184
Zachos M, Tondeur M, Griffiths A M.
Enteral nutritional therapy for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2007;
CD000542
- 185
Lochs H, Steinhardt H J, Klaus-Wentz B. et al .
Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Results
of the European Cooperative Crohn’s Disease Study. IV.
Gastroenterology.
1991;
101
881-888
- 186
Schutz T, Valentini L, Herbst B. et al .
ESPEN guidelines on enteral nutrition – summary.
Z Gastroenterol.
2006;
44
683-684
- 187
Gasche C, Berstad A, Befrits R. et al .
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory
bowel diseases.
Inflamm Bowel Dis.
2007;
13
1545-1553
- 188
Steinhart A H, Feagan B G, Wong C J. et al .
Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized
controlled trial.
Gastroenterology.
2002;
123
33-40
- 189
Summers R W, Switz D M, Sessions J T. et al .
National Cooperative Crohn’s Disease Study: results of drug treatment.
Gastroenterology.
1979;
77
847-869
- 190
Malchow Jr H, Ewe K, Brandes J W. et al .
European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment.
Gastroenterology.
1984;
86
249-266
- 191
Mielants H, Veys E M, Cuvelier C. et al .
HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel
histology in patients with HLA-B27 related arthritis.
J Rheumatol.
1985;
12
294-298
- 192
Herfarth H, Gross V, Andus T. et al .
Analysis of the therapeutic efficacy of different doses of budesonide in patients
with active Crohn’s ileocolitis depending on disease activity and localization.
Int J Colorectal Dis.
2004;
19
147-152
- 193
Beaugerie L, Seksik P, Nion-Larmurier I. et al .
Predictors of Crohn’s disease.
Gastroenterology.
2006;
130
650-656
- 194
Fichera A, Lovadina S, Rubin M. et al .
Patterns and operative treatment of recurrent Crohn’s disease: a prospective longitudinal
study.
Surgery.
2006;
140
649-654
- 195
Yamamoto T, Fazio V W, Tekkis P P.
Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and
meta-analysis.
Dis Colon Rectum.
2007;
50
1968-1986
- 196
Andant C, Godeberge B, Chaussade S. et al .
Clinical course of symptomatic duodeno-jejunal Crohn’s disease.
Gastroenterol Clin Biol.
1999;
23
1134-1138
- 197
Kugathasan S, Werlin S L, Martinez A. et al .
Prolonged duration of response to infliximab in early but not late pediatric Crohn’s
disease.
Am J Gastroenterol.
2000;
95
3189-3194
- 198
Lionetti P, Bronzini F, Salvestrini C. et al .
Response to infliximab is related to disease duration in paediatric Crohn’s disease.
Aliment Pharmacol Ther.
2003;
18
425-431
- 199
Tremaine W J.
Gastroduodenal Crohn’s disease: medical management.
Inflamm Bowel Dis.
2003;
9
127-128; discussion 131
- 200
Mottet C, Juillerat P, Gonvers J J. et al .
Treatment of gastroduodenal Crohn’s disease.
Digestion.
2005;
71
37-40
- 201
Miehsler W, Puspok A, Oberhuber T. et al .
Impact of different therapeutic regimens on the outcome of patients with Crohn’s disease
of the upper gastrointestinal tract.
Inflamm Bowel Dis.
2001;
7
99-105
- 202
Sandborn W, Sutherland L, Pearson D. et al .
Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease.
Cochrane Database Syst Rev.
2000;
CD000545
- 203
Pearson D C, May G R, Fick G. et al .
Azathioprine for maintaining remission of Crohn’s disease.
Cochrane Database Syst Rev.
2000;
CD000067
- 204
Bastida PAz G, Nos Mateu P, Aguas Peris M. et al .
Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in
inflammatory bowel disease.
Gastroenterol Hepatol.
2007;
30
511-516
- 205
Alfadhli A A, McDonald J W, Feagan B G.
Methotrexate for induction of remission in refractory Crohn’s disease.
Cochrane Database Syst Rev.
2005;
CD003459
- 206
Fraser A G.
Methotrexate: first-line or second-line immunomodulator?.
Eur J Gastroenterol Hepatol.
2003;
15
225-231
- 207
Mack D R, Young R, Kaufman S S. et al .
Methotrexate in patients with Crohn’s disease after 6-mercaptopurine.
J Pediatr.
1998;
132
830-835
- 208
Uhlen S, Belbouab R, Narebski K. et al .
Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study.
Inflamm Bowel Dis.
2006;
12
1053-1057
- 209
Ravikumara M, Hinsberger A, Spray C H.
Role of methotrexate in the management of Crohn disease.
J Pediatr Gastroenterol Nutr.
2007;
44
427-430
- 210
Rogers P, Tybulewicz A T, Pieterse L. et al .
Use of Methotrexate to Induce and Maintain Remission in Crohn’s Disease: A Regional
Cohort Study.
J Pediatr Gastroenterol Nutr.
2006;
43
S26
- 211
Targan S R, Hanauer S B, Deventer S J. et al .
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha
for Crohn’s disease. Crohn’s Disease cA2 Study Group.
N Engl J Med.
1997;
337
1029-1035
- 212
Hanauer S B, Sandborn W J, Rutgeerts van P. et al .
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:
the CLASSIC-I trial.
Gastroenterology.
2006;
130
323-333; quiz 591
- 213
Dullemen H M, Deventer van S J, Hommes D W. et al .
Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody
(cA2).
Gastroenterology.
1995;
109
129-135
- 214
Sandborn W J, Feagan B G, Stoinov van S. et al .
Certolizumab pegol for the treatment of Crohn’s disease.
N Engl J Med.
2007;
357
228-238
- 215
Schreiber S, Rutgeerts P, Fedorak R N. et al .
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment
of Crohn’s disease.
Gastroenterology.
2005;
129
807-818
- 216
Hanauer S B, Feagan B G, Lichtenstein G R. et al .
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial.
Lancet.
2002;
359
1541-1549
- 217
Colombel J F, Sandborn W J, Rutgeerts P. et al .
Adalimumab for maintenance of clinical response and remission in patients with Crohn’s
disease: the CHARM trial.
Gastroenterology.
2007;
132
52-65
- 218
Sandborn W J, Hanauer S B, Rutgeerts P. et al .
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II
trial.
Gut.
2007;
56
1232-1239
- 219
Schreiber S, Khaliq-Kareemi M, Lawrance I C. et al .
Maintenance therapy with certolizumab pegol for Crohn’s disease.
N Engl J Med.
2007;
357
239-250
- 220
Schreiber S.
Crohn’s disease – infliximab, adalimumab and certolizumab-pegol: clinical value of
anti-TNF-alpha treatment.
Dtsch Med Wochenschr.
2007;
132
1770-1774
- 221
Franchimont N, Putzeys V, Collette J. et al .
Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease.
Aliment Pharmacol Ther.
2004;
20
607-614
- 222
Bernstein M, Irwin S, Greenberg G R.
Maintenance infliximab treatment is associated with improved bone mineral density
in Crohn’s disease.
Am J Gastroenterol.
2005;
100
2031-2035
- 223
Mauro M, Radovic V, Armstrong D.
Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients.
Can J Gastroenterol.
2007;
21
637-642
- 224
Rutgeerts P, Diamond R H, Bala M. et al .
Scheduled maintenance treatment with infliximab is superior to episodic treatment
for the healing of mucosal ulceration associated with Crohn’s disease.
Gastrointest Endosc.
2006;
63
433-442; quiz 464
- 225
Froslie K F, Jahnsen J, Moum B A. et al .
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based
cohort.
Gastroenterology.
2007;
133
412-422
- 226
Present D H, Korelitz B I, Wisch N. et al .
Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind
study.
N Engl J Med.
1980;
302
981-987
- 227
Feagan B G, Rochon J, Fedorak R N. et al .
Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study
Group Investigators.
N Engl J Med.
1995;
332
292-297
- 228
Cosnes J, Cattan S, Blain A. et al .
Long-term evolution of disease behavior of Crohn’s disease.
Inflamm Bowel Dis.
2002;
8
244-250
- 229
Rutgeerts P.
Strategies in the prevention of post-operative recurrence in Crohn’s disease.
Best Pract Res Clin Gastroenterol.
2003;
17
63-73
- 230
D’Haens G R, Geboes K, Peeters M. et al .
Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents
in excluded ileum.
Gastroenterology.
1998;
114
262-267
- 231
Rutgeerts P, Hiele M, Geboes K. et al .
Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after
ileal resection.
Gastroenterology.
1995;
108
1617-1621
- 232
Lemann M, Mary J Y, Duclos B. et al .
Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized
placebo-controlled trial.
Gastroenterology.
2006;
130
1054-1061
- 233
Navarro F A, Hanauer S B, Kirschner B S.
Effect of long-term low-dose prednisone on height velocity and disease activity in
pediatric and adolescent patients with Crohn disease.
J Pediatr Gastroenterol Nutr.
2007;
45
312-318
- 234
Hyams J, Crandall W, Kugathasan S. et al .
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe
Crohn’s disease in children.
Gastroenterology.
2007;
132
863-873; quiz 1165 – 1166
- 235
Newby E A, Sawczenko A, Thomas A G. et al .
Interventions for growth failure in childhood Crohn’s disease.
Cochrane Database Syst Rev.
2005;
CD003873
- 236
Heuschkel R B, Menache C C, Megerian J T. et al .
Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in
children.
J Pediatr Gastroenterol Nutr.
2000;
31
8-15
- 237
Afzal N A, Davies S, Paintin M. et al .
Colonic Crohn’s disease in children does not respond well to treatment with enteral
nutrition if the ileum is not involved.
Dig Dis Sci.
2005;
50
1471-1475
- 238
Levine A, Weizman Z, Broide E. et al .
A comparison of budesonide and prednisone for the treatment of active pediatric Crohn
disease.
J Pediatr Gastroenterol Nutr.
2003;
36
248-252
- 239
Brignola C, Campieri M, Bazzocchi G. et al .
A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease.
Gastroenterology.
1986;
91
1490-1494
- 240
Schreiber S, Nikolaus S, Hampe J. et al .
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease.
Lancet.
1999;
353
459-461
- 241
Papadakis K A, Yang H, Ippoliti A. et al .
Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations.
Inflamm Bowel Dis.
2007;
13
524-530
- 242
Devlin S M, Yang H, Ippoliti A. et al .
NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients
and their unaffected relatives.
Gastroenterology.
2007;
132
576-586
- 243
Mei L, Targan S R, Landers C J. et al .
Familial expression of anti-Escherichia coli outer membrane porin C in relatives of
patients with Crohn’s disease.
Gastroenterology.
2006;
130
1078-1085
- 244
Targan S R, Landers C J, Yang H. et al .
Antibodies to CBir1 flagellin define a unique response that is associated independently
with complicated Crohn’s disease.
Gastroenterology.
2005;
128
2020-2028
- 245
Munkholm P, Langholz E, Davidsen M. et al .
Disease activity courses in a regional cohort of Crohn’s disease patients.
Scand J Gastroenterol.
1995;
30
699-706
- 246
Sahmoud T, Hoctin-Boes G, Modigliani R. et al .
Identifying patients with a high risk of relapse in quiescent Crohn’s disease. The
GETAID Group. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives.
Gut.
1995;
37
811-818
- 247
Kamm M A.
Review article: chronic active disease and maintaining remission in Crohn’s disease.
Aliment Pharmacol Ther.
2004;
20 (Suppl 4)
102-105
- 248
Feagan B G.
Maintenance therapy for inflammatory bowel disease.
Am J Gastroenterol.
2003;
98
S6-S17
- 249
Akobeng A K, Gardener E.
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s
Disease.
Cochrane Database Syst Rev.
2005;
CD003715
- 250
Mahid S S, Minor K S, Stromberg A J. et al .
Active and passive smoking in childhood is related to the development of inflammatory
bowel disease.
Inflamm Bowel Dis.
2007;
13
431-438
- 251
Mahid S S, Minor K S, Soto R E. et al .
Smoking and inflammatory bowel disease: a meta-analysis.
Mayo Clin Proc.
2006;
81
1462-1471
- 252
Timmer A, Sutherland L R, Martin F.
Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease.
The Canadian Mesalamine for Remission of Crohn’s Disease Study Group.
Gastroenterology.
1998;
114
1143-1150
- 253
Kane S V, Flicker M, Katz-Nelson F.
Tobacco use is associated with accelerated clinical recurrence of Crohn’s disease
after surgically induced remission.
J Clin Gastroenterol.
2005;
39
32-35
- 254
Simms L, Steinhart A H.
Budesonide for maintenance of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2001;
CD002913
- 255
Steinhart A H, Ewe K, Griffiths A M. et al .
Corticosteroids for maintenance of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2003;
CD000301
- 256
Ludwig D, Stange E F.
Efficacy of azathioprine in the treatment of chronic active Crohn’s disease: prospective
one-year follow-up study. German Imurek Study Group.
Z Gastroenterol.
1999;
37
1085-1091
- 257
Bokemeyer B, Teml A, Roggel C. et al .
Adherence to thiopurine treatment in out-patients with Crohn’s disease.
Aliment Pharmacol Ther.
2007;
26
217-225
- 258
Reinshagen M, Schutz E, Armstrong V W. et al .
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission
rates than standard therapy in chronic active crohn disease: results from a randomized,
controlled, open trial.
Clin Chem.
2007;
53
1306-1314
- 259
Lemann M, Mary J Y, Colombel J F. et al .
A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients
in long-term remission on azathioprine.
Gastroenterology.
2005;
128
1812-1818
- 260
Vilien M, Dahlerup J F, Munck L K. et al .
Randomized controlled azathioprine withdrawal after more than two years treatment
in Crohn’s disease: increased relapse rate the following year.
Aliment Pharmacol Ther.
2004;
19
1147-1152
- 261
Rutgeerts P, Feagan B G, Lichtenstein G R. et al .
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s
disease.
Gastroenterology.
2004;
126
402-413
- 262
Hanauer S B, Wagner C L, Bala M. et al .
Incidence and importance of antibody responses to infliximab after maintenance or
episodic treatment in Crohn’s disease.
Clin Gastroenterol Hepatol.
2004;
2
542-553
- 263
Vermeire S, Noman M, Van Assche G. et al .
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation
of antibodies to infliximab in Crohn’s disease.
Gut.
2007;
56
1226-1231
- 264
Schroder O, Blumenstein I, Stein J.
Combining infliximab with methotrexate for the induction and maintenance of remission
in refractory Crohn’s disease: a controlled pilot study.
Eur J Gastroenterol Hepatol.
2006;
18
11-16
- 265
Rutgeerts P, D’Haens G, Targan S. et al .
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab)
to maintain remission in Crohn’s disease.
Gastroenterology.
1999;
117
761-769
- 266
Sandborn W J, Rutgeerts P, Enns R. et al .
Adalimumab induction therapy for Crohn disease previously treated with infliximab:
a randomized trial.
Ann Intern Med.
2007;
146
829-838
- 267
Rutgeerts P, Geboes K, Vantrappen G. et al .
Predictability of the postoperative course of Crohn’s disease.
Gastroenterology.
1990;
99
956-963
- 268
Froehlich F, Juillerat P, Pittet V. et al .
Maintenance of surgically induced remission of Crohn’s disease.
Digestion.
2007;
76
130-135
- 269
Hanauer S B, Korelitz B I, Rutgeerts P. et al .
Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine,
or placebo: a 2-year trial.
Gastroenterology.
2004;
127
723-729
- 270
Ardizzone S, Maconi G, Sampietro G M. et al .
Azathioprine and mesalamine for prevention of relapse after conservative surgery for
Crohn’s disease.
Gastroenterology.
2004;
127
730-740
- 271
Sutherland L R, Steinhart A H.
Mesalazine as a maintenance treatment in Crohn’s disease.
Gut.
1998;
42
143-144
- 272
Akobeng A K.
Review article: the evidence base for interventions used to maintain remission in
Crohn’s disease.
Aliment Pharmacol Ther.
2008;
27
11-18
- 273
Sandborn W J, Feagan B G, Lichtenstein G R.
Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms
for induction and maintenance of remission.
Aliment Pharmacol Ther.
2007;
26
987-1003
- 274
Rahimi R, Nikfar S, Rezaie A. et al .
A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s
disease.
Clin Ther.
2006;
28
1983-1988
- 275
Prantera C, Berto E, Scribano M L. et al .
Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole
and ciprofloxacin.
Ital J Gastroenterol Hepatol.
1998;
30
602-606
- 276
Takagi S, Utsunomiya K, Kuriyama S. et al .
Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease:
A randomized-controlled trial.
Aliment Pharmacol Ther.
2006;
24
1333-1340
- 277
Wilschanski M, Sherman P, Pencharz P. et al .
Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease.
Gut.
1996;
38
543-548
- 278 Dachverband Osteologie .Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten
Osteoporose. Zugriff: 7.5.2008 Online im WWW. URL: http://www.lutherhaus.de/osteo/leitlinien-dvo/PDFs/DVO-Leitlinie%
20Glukokortikoid-Osteoporose% 20Version% 2006 – 09 – 07 % 20.pdf
- 279
Narendranathan M, Sandler R S, Suchindran C M. et al .
Male infertility in inflammatory bowel disease.
J Clin Gastroenterol.
1989;
11
403-406
- 280
O’Morain C, Smethurst P, Dore C J. et al .
Reversible male infertility due to sulphasalazine: studies in man and rat.
Gut.
1984;
25
1078-1084
- 281
Birnie G G, McLeod T I, Watkinson G.
Incidence of sulphasalazine-induced male infertility.
Gut.
1981;
22
452-455
- 282
Levi A J, Fisher A M, Hughes L. et al .
Male infertility due to sulphasalazine.
Lancet.
1979;
2
276-278
- 283
Toth A.
Reversible toxic effect of salicylazosulfapyridine on semen quality.
Fertil Steril.
1979;
31
538-540
- 284
Gonvers J J, Juillerat P, Mottet C. et al .
Maintenance of remission in Crohn’s disease.
Digestion.
2005;
71
41-48
- 285
Schedel J, Godde A, Schutz E. et al .
Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations
in patients with chronic inflammatory diseases.
Ann N Y Acad Sci.
2006;
1069
477-491
- 286
Colombel J F, Ferrari N, Debuysere H. et al .
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease
and severe myelosuppression during azathioprine therapy.
Gastroenterology.
2000;
118
1025-1030
- 287
Braun J, Kastner P, Flaxenberg P. et al .
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration
of methotrexate in patients with active rheumatoid arthritis: results of a six-month,
multicenter, randomized, double-blind, controlled, phase IV trial.
Arthritis Rheum.
2008;
58
73-81
- 288
Feagan B G, Fedorak R N, Irvine E J. et al .
A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s
disease. North American Crohn’s Study Group Investigators.
N Engl J Med.
2000;
342
1627-1632
- 289
Ortiz Z, Shea B, Suarez Almazor M. et al .
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate
for rheumatoid arthritis.
Cochrane Database Syst Rev.
2000;
CD000951
- 290
Arnott I D, Watts D, Satsangi J.
Azathioprine and anti-TNF alpha therapies in Crohn’s disease: a review of pharmacology,
clinical efficacy and safety.
Pharmacol Res.
2003;
47
1-10
- 291
Colombel J F, Loftus E V, Tremaine W J. et al .
The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic
experience in 500 patients.
Gastroenterology.
2004;
126
19-31
- 292
Mow W S, Abreu-Martin M T, Papadakis K A. et al .
High incidence of anergy in inflammatory bowel disease patients limits the usefulness
of PPD screening before infliximab therapy.
Clin Gastroenterol Hepatol.
2004;
2
309-313
- 293
Sellam Jr J, Hamdi H, Roy C. et al .
Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis
of latent tuberculosis before anti-TNF therapy.
Ann Rheum Dis.
2007;
66
1610-1615
- 294
Listing J, Strangfeld A, Kary S. et al .
Infections in patients with rheumatoid arthritis treated with biologic agents.
Arthritis Rheum.
2005;
52
3403-3412
- 295
Dixon W G, Watson K, Lunt M. et al .
Rates of serious infection, including site-specific and bacterial intracellular infection,
in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results
from the British Society for Rheumatology Biologics Register.
Arthritis Rheum.
2006;
54
2368-2376
- 296
Curtis J R, Patkar N, Xie A. et al .
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to
tumor necrosis factor alpha antagonists.
Arthritis Rheum.
2007;
56
1125-1133
- 297
Rosh J R, Gross T, Mamula P. et al .
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease:
a cautionary tale?.
Inflamm Bowel Dis.
2007;
13
1024-1030
- 298
Comby E, Tanaff P, Mariotte D. et al .
Evolution of antinuclear antibodies and clinical patterns in patients with active
rheumatoid arthritis with longterm infliximab therapy.
J Rheumatol.
2006;
33
24-30
- 299
Costa M F, Said N R, Zimmermann B.
Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
Semin Arthritis Rheum.
2008;
37
381-387
- 300
Baird D D, Narendranathan M, Sandler R S.
Increased risk of preterm birth for women with inflammatory bowel disease.
Gastroenterology.
1990;
99
987-994
- 301
Khosla R, Willoughby C P, Jewell D P.
Crohn’s disease and pregnancy.
Gut.
1984;
25
52-56
- 302
Woolfson K, Cohen Z, McLeod R S.
Crohn’s disease and pregnancy.
Dis Colon Rectum.
1990;
33
869-873
- 303
Fonager K, Sorensen H T, Olsen J. et al .
Pregnancy outcome for women with Crohn’s disease: a follow-up study based on linkage
between national registries.
Am J Gastroenterol.
1998;
93
2426-2430
- 304
Baiocco P J, Korelitz B I.
The influence of inflammatory bowel disease and its treatment on pregnancy and fetal
outcome.
J Clin Gastroenterol.
1984;
6
211-216
- 305
Mayberry J F, Weterman I T.
European survey of fertility and pregnancy in women with Crohn’s disease: a case control
study by European collaborative group.
Gut.
1986;
27
821-825
- 306
Hudson M, Flett G, Sinclair T S. et al .
Fertility and pregnancy in inflammatory bowel disease.
Int J Gynaecol Obstet.
1997;
58
229-237
- 307
Ravid A, Richard C S, Spencer L M. et al .
Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative
colitis.
Dis Colon Rectum.
2002;
45
1283-1288
- 308
Ording Olsen K, Juul S, Berndtsson I. et al .
Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery
compared with a population sample.
Gastroenterology.
2002;
122
15-19
- 309
Juhasz E S, Fozard B, Dozois R R. et al .
Ileal pouch-anal anastomosis function following childbirth. An extended evaluation.
Dis Colon Rectum.
1995;
38
159-165
- 310
Hanan I M, Kirsner J B.
Inflammatory bowel disease in the pregnant woman.
Clin Perinatol.
1985;
12
669-682
- 311
Larzilliere I, Beau P.
Chronic inflammatory bowel disease and pregnancy. Case control study.
Gastroenterol Clin Biol.
1998;
22
1056-1060
- 312
Miller J P.
Inflammatory bowel disease in pregnancy: a review.
J R Soc Med.
1986;
79
221-225
- 313
Korelitz B I.
Inflammatory bowel disease and pregnancy.
Gastroenterol Clin North Am.
1998;
27
213-224
- 314
Fedorkow D M, Persaud D, Nimrod C A.
Inflammatory bowel disease: a controlled study of late pregnancy outcome.
Am J Obstet Gynecol.
1989;
160
998-1001
- 315
Mogadam M, Korelitz B I, Ahmed S W. et al .
The course of inflammatory bowel disease during pregnancy and postpartum.
Am J Gastroenterol.
1981;
75
265-269
- 316
Alstead E M.
Inflammatory bowel disease in pregnancy.
Postgrad Med J.
2002;
78
23-26
- 317
Castile R G, Telander R L, Cooney D R. et al .
Crohn’s disease in children: assessment of the progression of disease, growth, and
prognosis.
J Pediatr Surg.
1980;
15
462-469
- 318
Nwokolo C U, Tan W C, Andrews H A. et al .
Surgical resections in parous patients with distal ileal and colonic Crohn’s disease.
Gut.
1994;
35
220-223
- 319
Mahadevan U, Kane S.
American gastroenterological association institute technical review on the use of
gastrointestinal medications in pregnancy.
Gastroenterology.
2006;
131
283-311
- 320
Ilnyckyji A, Blanchard J F, Rawsthorne P. et al .
Perianal Crohn’s disease and pregnancy: role of the mode of delivery.
Am J Gastroenterol.
1999;
94
3274-3278
- 321
Nelson H, Dozois R R, Kelly K A. et al .
The effect of pregnancy and delivery on the ileal pouch-anal anastomosis functions.
Dis Colon Rectum.
1989;
32
384-388
- 322
Nicholl M C, Thompson J M, Cocks P S.
Stomas and pregnancy.
Aust N Z J Obstet Gynaecol.
1993;
33
322-324
- 323
Ramalingam T, Box B, Mortensen N M.
Pregnancy delivery and pouch function after ileal pouch-anal anastomosis for ulcerative
colitis.
Dis Colon Rectum.
2003;
46
1292
- 324
Brandt L J, Estabrook S G, Reinus J F.
Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal
involvement in women with Crohn’s disease.
Am J Gastroenterol.
1995;
90
1918-1922
- 325
Edwards J T, Radford-Smith G L, Florin T H.
Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical
characteristics.
J Gastroenterol Hepatol.
2001;
16
1235-1238
- 326
Cross R K, Wilson K T, Binion D G.
Narcotic use in patients with Crohn’s disease.
Am J Gastroenterol.
2005;
100
2225-2229
- 327
Janke K H, Klump B, Gregor M. et al .
Determinants of life satisfaction in inflammatory bowel disease.
Inflamm Bowel Dis.
2005;
11
272-286
- 328
Cross R K, Wilson K T, Binion D G.
Polypharmacy and Crohn’s disease.
Aliment Pharmacol Ther.
2005;
21
1211-1216
- 329
Kopf A, Janson W, Stein C.
Anwendungsmöglichkeiten fur Opioide bei chronischem Nichttumorschmerz.
Anaesthesist.
2003;
52
103-114
- 330
Gerson L B, Triadafilopoulos G.
Palliative care in inflammatory bowel disease: an evidence-based approach.
Inflamm Bowel Dis.
2000;
6
228-243
- 331
Forrest K, Symmons D, Foster P.
Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory
drugs associated with exacerbations of inflammatory bowel disease?.
Aliment Pharmacol Ther.
2004;
20
1035-1043
- 332
Arundel C, Lewis J H.
Drug-induced liver disease in 2006.
Curr Opin Gastroenterol.
2007;
23
244-254
- 333
Kaplan M A, Korelitz B I.
Narcotic dependence in inflammatory bowel disease.
J Clin Gastroenterol.
1988;
10
275-278
- 334
Wambach S, Rohr P, Häuser W.
Opioidtherapiemissbrauch bei anhaltender somatoformer Schmerzstörung zur Indikationsdiskussion
von Opioiden bei chronischen benignen Schmerzsyndromen aus psychosomatisch-schmerztherapeutischer
Sicht.
Schmerz.
2001;
15
254-264
- 335
Jones J L, Loftus E V.
Avoiding the vicious cycle of prolonged opioid use in Crohn’s disease.
Am J Gastroenterol.
2005;
100
2230-2232
- 336
White Jr M, Shah N, Lindley K. et al .
Pain management in fulminating ulcerative colitis.
Paediatr Anaesth.
2006;
16
1148-1152
- 337
Minderhoud I M, Oldenburg B, Wismeijer J A. et al .
IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships
with quality of life and coping behavior.
Dig Dis Sci.
2004;
49
469-474
- 338
Simren M, Axelsson J, Gillberg R. et al .
Quality of life in inflammatory bowel disease in remission: the impact of IBS-like
symptoms and associated psychological factors.
Am J Gastroenterol.
2002;
97
389-396
- 339
Spiller R, Aziz Q, Creed F. et al .
Guidelines on the irritable bowel syndrome: mechanisms and practical management.
Gut.
2007;
56
1770-1798
- 340
Heuman R, Boeryd B, Bolin T. et al .
The influence of disease at the margin of resection on the outcome of Crohn’s disease.
Br J Surg.
1983;
70
519-521
- 341
Solberg I C, Vatn M H, Hoie O. et al .
Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year
follow-up study.
Clin Gastroenterol Hepatol.
2007;
5
1430-1438
- 342
Graadal O, Nygaard K.
Crohn disease. Long-term effects of surgical treatment.
Tidsskr Nor Laegeforen.
1994;
114
1603-1605
- 343
Nordgren S R, Fasth S B, Oresland T O. et al .
Long-term follow-up in Crohn’s disease. Mortality, morbidity, and functional status.
Scand J Gastroenterol.
1994;
29
1122-1128
- 344
Weston L A, Roberts P L, Schoetz D J. et al .
Ileocolic resection for acute presentation of Crohn’s disease of the ileum.
Dis Colon Rectum.
1996;
39
841-846
- 345
Kim N K, Senagore A J, Luchtefeld M A. et al .
Long-term outcome after ileocecal resection for Crohn’s disease.
Am Surg.
1997;
63
627-633
- 346
Tillinger Jr W, Mittermaier C, Lochs H. et al .
Health-related quality of life in patients with Crohn’s disease: influence of surgical
operation – a prospective trial.
Dig Dis Sci.
1999;
44
932-938
- 347
Golfieri R, Cappelli A, Giampalma E. et al .
CT-guided percutaneous pelvic abscess drainage in Crohn’s disease.
Tech Coloproctol.
2006;
10
99-105
- 348
Yamaguchi A, Matsui T, Sakurai T. et al .
The clinical characteristics and outcome of intraabdominal abscess in Crohn’s disease.
J Gastroenterol.
2004;
39
441-448
- 349
Gervais D A, Hahn P F, O’Neill M J. et al .
Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term
outcomes during 14 years.
Radiology.
2002;
222
645-651
- 350
Garcia J C, Persky S E, Bonis P A. et al .
Abscesses in Crohn’s disease: outcome of medical versus surgical treatment.
J Clin Gastroenterol.
2001;
32
409-412
- 351
Michelassi F, Upadhyay G A.
Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn’s
disease.
J Surg Res.
2004;
117
71-78
- 352
Sampietro G M, Sartani A, Danelli P. et al .
Strictureplasty in the surgical treatment of complicated Crohn’s disease.
Ann Ital Chir.
2003;
74
659-663
- 353
Tonelli F, Fedi M, Paroli G M. et al .
Indications and results of side-to-side isoperistaltic strictureplasty in Crohn’s
disease.
Dis Colon Rectum.
2004;
47
494-501
- 354
Shatari T, Clark M A, Yamamoto T. et al .
Long strictureplasty is as safe and effective as short strictureplasty in small-bowel
Crohn’s disease.
Colorectal Dis.
2004;
6
438-441
- 355
Poggioli G, Laureti S, Pierangeli F. et al .
A new model of strictureplasty for multiple and long stenoses in Crohn’s ileitis:
side-to-side diseased to disease-free anastomosis.
Dis Colon Rectum.
2003;
46
127-130
- 356
Tichansky D, Cagir B, Yoo E. et al .
Strictureplasty for Crohn’s disease: meta-analysis.
Dis Colon Rectum.
2000;
43
911-919
- 357
Roy P, Kumar D.
Strictureplasty for active Crohn’s disease.
Int J Colorectal Dis.
2006;
21
427-432
- 358
Fearnhead N S, Chowdhury R, Box B. et al .
Long-term follow-up of strictureplasty for Crohn’s disease.
Br J Surg.
2006;
93
475-482
- 359
Dietz D W, Fazio V W, Laureti S. et al .
Strictureplasty in diffuse Crohn’s jejunoileitis: safe and durable.
Dis Colon Rectum.
2002;
45
764-770
- 360
Broering D C, Eisenberger C F, Koch A. et al .
Strictureplasty for large bowel stenosis in Crohn’s disease: quality of life after
surgical therapy.
Int J Colorectal Dis.
2001;
16
81-87
- 361
Broering D C, Eisenberger C F, Koch A. et al .
Quality of life after surgical therapy of small bowel stenosis in Crohn’s disease.
Dig Surg.
2001;
18
124-130
- 362
Dietz D W, Laureti S, Strong S A. et al .
Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small
bowel Crohn’s disease.
J Am Coll Surg.
2001;
192
330-337; discussion 337 – 338
- 363
Yamamoto T, Allan R N, Keighley M R.
Long-term outcome of surgical management for diffuse jejunoileal Crohn’s disease.
Surgery.
2001;
129
96-102
- 364
Sampietro G M, Cristaldi M, Maconi G. et al .
A prospective, longitudinal study of nonconventional strictureplasty in Crohn’s disease.
J Am Coll Surg.
2004;
199
8-20; discussion 20 – 22
- 365
Benoist S, Panis Y, Beaufour A. et al .
Laparoscopic ileocecal resection in Crohn’s disease: a case-matched comparison with
open resection.
Surg Endosc.
2003;
17
814-818
- 366
Tabet J, Hong D, Kim C W. et al .
Laparoscopic versus open bowel resection for Crohn’s disease.
Can J Gastroenterol.
2001;
15
237-242
- 367
Marcello P W, Milsom J W, Wong S K. et al .
Laparoscopic restorative proctocolectomy: case-matched comparative study with open
restorative proctocolectomy.
Dis Colon Rectum.
2000;
43
604-608
- 368
Milsom J W, Hammerhofer K A, Bohm B. et al .
Prospective, randomized trial comparing laparoscopic vs. conventional surgery for
refractory ileocolic Crohn’s disease.
Dis Colon Rectum.
2001;
44
1-8; discussion 8 – 9
- 369
Maartense S, Dunker M S, Slors J F. et al .
Laparoscopic-assisted versus open ileocolic resection for Crohn’s disease: a randomized
trial.
Ann Surg.
2006;
243
143-149; discussion 150 – 143
- 370
Tilney H S, Constantinides V A, Heriot A G. et al .
Comparison of laparoscopic and open ileocecal resection for Crohn’s disease: a metaanalysis.
Surg Endosc.
2006;
20
1036-1044
- 371
Rosman A S, Melis M, Fichera A.
Metaanalysis of trials comparing laparoscopic and open surgery for Crohn’s disease.
Surg Endosc.
2005;
19
1549-1555
- 372
Bernell O, Lapidus A, Hellers G.
Recurrence after colectomy in Crohn’s colitis.
Dis Colon Rectum.
2001;
44
647-654; discussion 654
- 373
Allan A, Andrews H, Hilton C J. et al .
Segmental colonic resection is an appropriate operation for short skip lesions due
to Crohn’s disease in the colon.
World J Surg.
1989;
13
611-614; discussion 615 – 616
- 374
Yamamoto T, Keighley M R.
Proctocolectomy is associated with a higher complication rate but carries a lower
recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis.
Scand J Gastroenterol.
1999;
34
1212-1215
- 375
Tonelli F, Paroli G M.
Colorectal Crohn’s disease: indications to surgical treatment.
Ann Ital Chir.
2003;
74
665-672
- 376
Longo W E, Ballantyne G H, Cahow C E.
Treatment of Crohn’s colitis. Segmental or total colectomy?.
Arch Surg.
1988;
123
588-590
- 377
Andersson P, Olaison G, Hallbook O. et al .
Segmental resection or subtotal colectomy in Crohn’s colitis?.
Dis Colon Rectum.
2002;
45
47-53
- 378
Tekkis P P, Purkayastha S, Lanitis S. et al .
A comparison of segmental v. subtotal/total colectomy for colonic Crohn’s disease:
a meta-analysis.
Colorectal Dis.
2006;
8
82-90
- 379
Fichera A, McCormack R, Rubin M A. et al .
Long-term outcome of surgically treated Crohn’s colitis: a prospective study.
Dis Colon Rectum.
2005;
48
963-969
- 380
Kersting S, Bruewer M, Laukoetter M G. et al .
Intestinal cancer in patients with Crohn’s disease.
Int J Colorectal Dis.
2007;
22
411-417
- 381
Oca de J, Sanchez-Santos R, Rague J M. et al .
Long-term results of ileal pouch-anal anastomosis in Crohn’s disease.
Inflamm Bowel Dis.
2003;
9
171-175
- 382
Sagar P M, Dozois R R, Wolff B G.
Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease.
Dis Colon Rectum.
1996;
39
893-898
- 383
Handelsman J C, Gottlieb L M, Hamilton S R.
Crohn’s disease as a contraindication to Kock pouch (continent ileostomy).
Dis Colon Rectum.
1993;
36
840-843
- 384
Hyman N H, Fazio V W, Tuckson W B. et al .
Consequences of ileal pouch-anal anastomosis for Crohn’s colitis.
Dis Colon Rectum.
1991;
34
653-657
- 385
Panis Y, Poupard B, Nemeth J. et al .
Ileal pouch/anal anastomosis for Crohn’s disease.
Lancet.
1996;
347
854-857
- 386
Regimbeau J M, Panis Y, Pocard M. et al .
Long-term results of ileal pouch-anal anastomosis for colorectal Crohn’s disease.
Dis Colon Rectum.
2001;
44
769-778
- 387
Reese G E, Lovegrove R E, Tilney H S. et al .
The effect of Crohn’s disease on outcomes after restorative proctocolectomy.
Dis Colon Rectum.
2007;
50
239-250
- 388
Marchal L, D’Haens G, Van Assche G. et al .
The risk of post-operative complications associated with infliximab therapy for Crohn’s
disease: a controlled cohort study.
Aliment Pharmacol Ther.
2004;
19
749-754
- 389
Colombel J F, Loftus E V, Tremaine W J. et al .
Early postoperative complications are not increased in patients with Crohn’s disease
treated perioperatively with infliximab or immunosuppressive therapy.
Am J Gastroenterol.
2004;
99
878-883
- 390
Yamamoto Jr T, Allan R N, Keighley M R.
Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease.
Dis Colon Rectum.
2000;
43
1141-1145
- 391
Aberra F N, Lewis J D, Hass D. et al .
Corticosteroids and immunomodulators: postoperative infectious complication risk in
inflammatory bowel disease patients.
Gastroenterology.
2003;
125
320-327
- 392
Mahadevan U, Loftus E V, Tremaine W J. et al .
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated
with increased postoperative complications.
Inflamm Bowel Dis.
2002;
8
311-316
- 393
Heuschen U A, Hinz Jr U, Allemeyer E H. et al .
Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis
and familial adenomatous polyposis.
Ann Surg.
2002;
235
207-216
- 394
Bruewer M, Utech M, Rijcken E J. et al .
Preoperative steroid administration: effect on morbidity among patients undergoing
intestinal bowel resection for Crohns disease.
World J Surg.
2003;
27
1306-1310
- 395
Page M J, Poritz L S, Kunselman S J. et al .
Factors affecting surgical risk in elderly patients with inflammatory bowel disease.
J Gastrointest Surg.
2002;
6
606-613
- 396
Tay G S, Binion D G, Eastwood D. et al .
Multivariate analysis suggests improved perioperative outcome in Crohn’s disease patients
receiving immunomodulator therapy after segmental resection and/or strictureplasty.
Surgery.
2003;
134
565-572; discussion 572 – 563
- 397
Myrelid P, Andersson P, Sjödahl R. et al .
Immunosuppression for Crohn’s disease is associated with increased frequency of anastomotic
complications.
Colorectal Dis.
2004;
6
26
- 398
Weimann A, Braga M, Harsanyi L. et al .
ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation.
Clin Nutr.
2006;
25
224-244
- 399
Weimann A, Ebener C, Hauser L. et al .
Leitlinie Parenterale Ernährung: Chirurgie und Transplantation.
Aktuel Ernaehr Med.
2007;
32
S114-S123
- 400
Hellers G, Bergstrand O, Ewerth S. et al .
Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease.
Gut.
1980;
21
525-527
- 401
Schwartz D A, Loftus E V, Tremaine W J. et al .
The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota.
Gastroenterology.
2002;
122
875-880
- 402
Hellers Jr G.
Crohn’s disease in Stockholm county 1955 – 1974. A study of epidemiology, results
of surgical treatment and long-term prognosis.
Acta Chir Scand Suppl.
1979;
490
1-84
- 403
Schwartz D A, Wiersema M J, Dudiak K M. et al .
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under
anesthesia for evaluation of Crohn’s perianal fistulas.
Gastroenterology.
2001;
121
1064-1072
- 404
Bodegraven A A, Sloots C E, Felt-Bersma R J. et al .
Endosonographic evidence of persistence of Crohn’s disease-associated fistulas after
infliximab treatment, irrespective of clinical response.
Dis Colon Rectum.
2002;
45
39-45; discussion 45 – 36
- 405
Sloots C E, Felt-Bersma R J, Poen A C. et al .
Assessment and classification of fistula-in-ano in patients with Crohn’s disease by
hydrogen peroxide enhanced transanal ultrasound.
Int J Colorectal Dis.
2001;
16
292-297
- 406
Orsoni van P, Barthet M, Portier F. et al .
Prospective comparison of endosonography, magnetic resonance imaging and surgical
findings in anorectal fistula and abscess complicating Crohn’s disease.
Br J Surg.
1999;
86
360-364
- 407
Schwartz D A, White C M, Wise P E. et al .
Use of endoscopic ultrasound to guide combination medical and surgical therapy for
patients with Crohn’s perianal fistulas.
Inflamm Bowel Dis.
2005;
11
727-732
- 408
Buchanan G N, Bartram C I, Williams A B. et al .
Value of hydrogen peroxide enhancement of three-dimensional endoanal ultrasound in
fistula-in-ano.
Dis Colon Rectum.
2005;
48
141-147
- 409
West R L, Woude C J, Hansen B E. et al .
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal
fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study.
Aliment Pharmacol Ther.
2004;
20
1329-1336
- 410
Ardizzone van der S, Maconi G, Colombo E. et al .
Perianal fistulae following infliximab treatment: clinical and endosonographic outcome.
Inflamm Bowel Dis.
2004;
10
91-96
- 411
Wedemeyer J, Kirchhoff T, Manns M P. et al .
Transcutaneous perianal ultrasound (PAUS) for the imaging of fistulas and abscesses
in Crohn’s disease.
Z Gastroenterol.
2004;
42
1315-1320
- 412
Stewart L K, McGee J, Wilson S R.
Transperineal and transvaginal sonography of perianal inflammatory disease.
Am J Roentgenol.
2001;
177
627-632
- 413
Beets-Tan R G, Beets G L, Hoop A G. et al .
Preoperative MR imaging of anal fistulas: Does it really help the surgeon?.
Radiology.
2001;
218
75-84
- 414
Parks A G, Gordon P H, Hardcastle J D.
A classification of fistula-in-ano.
Br J Surg.
1976;
63
1-12
- 415
Bell S J, Williams A B, Wiesel van der P. et al .
The clinical course of fistulating Crohn’s disease.
Aliment Pharmacol Ther.
2003;
17
1145-1151
- 416
Thornton M, Solomon M J.
Long-term indwelling seton for complex anal fistulas in Crohn’s disease.
Dis Colon Rectum.
2005;
48
459-463
- 417
Rasul I, Wilson S R, MacRae H. et al .
Clinical and radiological responses after infliximab treatment for perianal fistulizing
Crohn’s disease.
Am J Gastroenterol.
2004;
99
82-88
- 418
Sandborn W J, Fazio V W, Feagan B G. et al .
AGA technical review on perianal Crohn’s disease.
Gastroenterology.
2003;
125
1508-1530
- 419
O’Donoghue D P, Hyland J M.
Perianal Crohn’s disease.
Eur J Gastroenterol Hepatol.
1997;
9
235-236
- 420
Sangwan Y P, Schoetz D J, Murray J J. et al .
Perianal Crohn’s disease. Results of local surgical treatment.
Dis Colon Rectum.
1996;
39
529-535
- 421
Lichtenstein G R.
Treatment of fistulizing Crohn’s disease.
Gastroenterology.
2000;
119
1132-1147
- 422
Bernstein L H, Frank M S, Brandt L J. et al .
Healing of perineal Crohn’s disease with metronidazole.
Gastroenterology.
1980;
79
357-365
- 423
Buchanan G N, Owen H A, Torkington Jr J. et al .
Long-term outcome following loose-seton technique for external sphincter preservation
in complex anal fistula.
Br J Surg.
2004;
91
476-480
- 424
Takesue Y, Ohge H, Yokoyama T. et al .
Long-term results of seton drainage on complex anal fistulae in patients with Crohn’s
disease.
J Gastroenterol.
2002;
37
912-915
- 425
Sonoda T, Hull T, Piedmonte M R. et al .
Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal
advancement flap.
Dis Colon Rectum.
2002;
45
1622-1628
- 426
Hagen S J, Baeten C G, Soeters P B. et al .
Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis
in a multistep strategy followed by definitive surgery of complex anal fistulas in
Crohn’s disease: a preliminary report.
Dis Colon Rectum.
2005;
48
758-767
- 427
Topstad D R, Panaccione van der R, Heine J A. et al .
Combined seton placement, infliximab infusion, and maintenance immunosuppressives
improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience.
Dis Colon Rectum.
2003;
46
577-583
- 428
Regueiro M, Mardini H.
Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct
to exam under anesthesia with seton placement.
Inflamm Bowel Dis.
2003;
9
98-103
- 429
Hyder S A, Travis S P, Jewell D P. et al .
Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment.
Dis Colon Rectum.
2006;
49
1837-1841
- 430
Lindsey I, Smilgin-Humphreys M M, Cunningham C. et al .
A randomized, controlled trial of fibrin glue vs. conventional treatment for anal
fistula.
Dis Colon Rectum.
2002;
45
1608-1615
- 431
Ozuner G, Hull T L, Cartmill J. et al .
Long-term analysis of the use of transanal rectal advancement flaps for complicated
anorectal/vaginal fistulas.
Dis Colon Rectum.
1996;
39
10-14
- 432
Scott N A, Nair A, Hughes L E.
Anovaginal and rectovaginal fistula in patients with Crohn’s disease.
Br J Surg.
1992;
79
1379-1380
- 433
Buhr H J, Kroesen A J, Herfarth C.
Surgical therapy of recurrent Crohn disease.
Chirurg.
1995;
66
764-773
- 434
Dejaco C, Harrer M, Waldhoer T. et al .
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease.
Aliment Pharmacol Ther.
2003;
18
1113-1120
- 435
Luna-Chadid M, Perez Calle J L, Mendoza J L. et al .
Predictors of response to infliximab in patients with fistulizing Crohn’s disease.
Rev Esp Enferm Dig.
2004;
96
379-381; 382 – 374
- 436
Poritz L S, Gagliano G A, McLeod R S. et al .
Surgical management of entero and colocutaneous fistulae in Crohn’s disease: 17 year’s
experience.
Int J Colorectal Dis.
2004;
19
481-485; discussion 486
- 437
Sands B E, Anderson F H, Bernstein C N. et al .
Infliximab maintenance therapy for fistulizing Crohn’s disease.
N Engl J Med.
2004;
350
876-885
- 438
Poritz L S, Rowe W A, Koltun W A.
Remicade does not abolish the need for surgery in fistulizing Crohn’s disease.
Dis Colon Rectum.
2002;
45
771-775
- 439
Sonnenberg A, Gavin M W.
Timing of surgery for enterovesical fistula in Crohn’s disease: decision analysis
using a time-dependent compartment model.
Inflamm Bowel Dis.
2000;
6
280-285
- 440
Brandt L J, Bernstein L H, Boley S J. et al .
Metronidazole therapy for perineal Crohn’s disease: a follow-up study.
Gastroenterology.
1982;
83
383-387
- 441
Jakobovits J, Schuster M M.
Metronidazole therapy for Crohn’s disease and associated fistulae.
Am J Gastroenterol.
1984;
79
533-540
- 442
Pearson D C, May G R, Fick G H. et al .
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
Ann Intern Med.
1995;
123
132-142
- 443
Lecomte T, Contou J F, Beaugerie L. et al .
Predictive factors of response of perianal Crohn’s disease to azathioprine or 6-mercaptopurine.
Dis Colon Rectum.
2003;
46
1469-1475
- 444
Korelitz B I, Adler D J, Mendelsohn R A. et al .
Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease.
Am J Gastroenterol.
1993;
88
1198-1205
- 445
Present D H, Rutgeerts P, Targan S. et al .
Infliximab for the treatment of fistulas in patients with Crohn’s disease.
N Engl J Med.
1999;
340
1398-1405
- 446
Sands B E, Blank M A, Patel K. et al .
Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab
in the ACCENT II Study.
Clin Gastroenterol Hepatol.
2004;
2
912-920
- 447
Lichtenstein G R, Yan S, Bala M. et al .
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures
in fistulizing Crohn’s disease.
Gastroenterology.
2005;
128
862-869
- 448
Farrell R J, Shah S A, Lodhavia P J. et al .
Clinical experience with infliximab therapy in 100 patients with Crohn’s disease.
Am J Gastroenterol.
2000;
95
3490-3497
- 449
Ricart E, Panaccione R, Loftus E V. et al .
Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first
100 patients.
Am J Gastroenterol.
2001;
96
722-729
- 450
Sandborn W J.
A critical review of cyclosporine therapy in inflammatoy bowel disease.
Inflamm Bowel Dis.
1995;
1
48-63
- 451
Sandborn W J.
Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated
proximal small bowel and fistulizing Crohn’s disease.
Am J Gastroenterol.
1997;
92
876-879
- 452
Fellermann K, Ludwig D, Stahl M. et al .
Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation
by tacrolimus (FK506).
Am J Gastroenterol.
1998;
93
1860-1866
- 453
Lowry P W, Weaver A L, Tremaine W J. et al .
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine
for treatment-refractory Crohn’s disease perianal fistulae.
Inflamm Bowel Dis.
1999;
5
239-245
- 454
Ierardi E, Principi M, Francavilla R. et al .
Oral tacrolimus long-term therapy in patients with Crohn’s disease and steroid resistance.
Aliment Pharmacol Ther.
2001;
15
371-377
- 455
Sandborn W J, Present D H, Isaacs K L. et al .
Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized,
placebo-controlled trial.
Gastroenterology.
2003;
125
380-388
- 456
Wenzl H H, Hinterleitner T A, Aichbichler B W. et al .
Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome.
Aliment Pharmacol Ther.
2004;
19
427-434
- 457
Ehrenpreis E D, Kane S V, Cohen L B. et al .
Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial.
Gastroenterology.
1999;
117
1271-1277
- 458
Vasiliauskas E A, Kam L Y, Abreu-Martin M T. et al .
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent
Crohn’s disease.
Gastroenterology.
1999;
117
1278-1287
- 459
Colombel J F, Mathieu D, Bouault J M. et al .
Hyperbaric oxygenation in severe perineal Crohn’s disease.
Dis Colon Rectum.
1995;
38
609-614
- 460
Vaughan D, Drumm B.
Treatment of fistulas with granulocyte colony-stimulating factor in a patient with
Crohn’s disease.
N Engl J Med.
1999;
340
239-240
- 461
Levy C, Tremaine W J.
Management of internal fistulas in Crohn’s disease.
Inflamm Bowel Dis.
2002;
8
106-111
- 462
Greenstein A J, Janowitz H D, Sachar D B.
The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study
of 700 patients.
Medicine (Baltimore).
1976;
55
401-412
- 463
Dougados M, Linden van der S, Juhlin R. et al .
The European Spondylarthropathy Study Group preliminary criteria for the classification
of spondylarthropathy.
Arthritis Rheum.
1991;
34
1218-1227
- 464
Orchard T R, Wordsworth B P, Jewell D P.
Peripheral arthropathies in inflammatory bowel disease: their articular distribution
and natural history.
Gut.
1998;
42
387-391
- 465
Vlam de K, Mielants H, Cuvelier C. et al .
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and
HLA association.
J Rheumatol.
2000;
27
2860-2865
- 466
Gran J T, Husby G.
Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects,
ulcerative colitis and Crohn’s disease.
Dig Dis.
1992;
10
274-294
- 467
Protzer U, Duchmann R, Hohler T. et al .
Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence,
manifestation pattern and HLA association.
Med Klin.
1996;
91
330-335
- 468
Braun J, Bollow M, Remlinger G. et al .
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.
Arthritis Rheum.
1998;
41
58-67
- 469
El Miedany Y, Youssef S, Ahmed I. et al .
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective
cox-2 inhibitor in inflammatory bowel diseases.
Am J Gastroenterol.
2006;
101
311-317
- 470
Sandborn W J, Stenson W F, Brynskov J. et al .
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized,
placebo-controlled, pilot study.
Clin Gastroenterol Hepatol.
2006;
4
203-211
- 471
Braun J, Brandt J, Listing J. et al .
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled
multicentre trial.
Lancet.
2002;
359
1187-1193
- 472
Generini S, Giacomelli R, Fedi R. et al .
Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on
the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
Ann Rheum Dis.
2004;
63
1664-1669
- 473
Herfarth H, Obermeier F, Andus T. et al .
Improvement of arthritis and arthralgia after treatment with infliximab (Remicade)
in a German prospective, open-label, multicenter trial in refractory Crohn’s disease.
Am J Gastroenterol.
2002;
97
2688-2690
- 474
Kaufman I, Caspi D, Yeshurun D. et al .
The effect of infliximab on extraintestinal manifestations of Crohn’s disease.
Rheumatol Int.
2005;
25
406-410
- 475
Rispo A, Scarpa R, Di Girolamo E. et al .
Infliximab in the treatment of extra-intestinal manifestations of Crohn’s disease.
Scand J Rheumatol.
2005;
34
387-391
- 476
Erlichman M, Holohan T V.
Bone densitometry: patients receiving prolonged steroid therapy.
Health Technol Assess (Rockv).
1996;
i-31
- 477
Ahmed S F, Horrocks I A, Patterson T. et al .
Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory
bowel disease: evaluation by age or bone area.
J Pediatr Gastroenterol Nutr.
2004;
38
276-280
- 478
Burnham J M, Shults J, Semeao E. et al .
Whole body BMC in pediatric Crohn disease: independent effects of altered growth,
maturation, and body composition.
J Bone Miner Res.
2004;
19
1961-1968
- 479
Fewtrell M S.
Bone densitometry in children assessed by dual × ray absorptiometry: uses and pitfalls.
Arch Dis Child.
2003;
88
795-798
- 480
Tirpitz von C, Klaus J, Steinkamp M. et al .
Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing
sodium fluoride and ibandronate.
Aliment Pharmacol Ther.
2003;
17
807-816
- 481
Compston J E.
Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis.
Curr Rheumatol Rep.
2007;
9
78-84
- 482
Bartram S A, Peaston R T, Rawlings D J. et al .
A randomized controlled trial of calcium with vitamin D, alone or in combination with
intravenous pamidronate, for the treatment of low bone mineral density associated
with Crohn’s disease.
Aliment Pharmacol Ther.
2003;
18
1121-1127
- 483
Siffledeen J S, Fedorak R N, Siminoski K. et al .
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone
mineral density in Crohn’s disease.
Clin Gastroenterol Hepatol.
2005;
3
122-132
- 484
Requena L, Sanchez Yus E.
Erythema nodosum.
Semin Cutan Med Surg.
2007;
26
114-125
- 485
Gregory B, Ho V C.
Cutaneous manifestations of gastrointestinal disorders. Part II.
J Am Acad Dermatol.
1992;
26
371-383
- 486
Kirsch B. et al .
Dermatosen bei chronisch entzündlichen Darmerkrankungen. Ergebnisse einer Untersuchung
von 119 Morbus Crohn/C. ulcerosa-Patienten.
Akt Dermatol.
1992;
18
17-22
- 487
Blitz N M, Rudikoff D.
Pyoderma gangrenosum.
Mt Sinai J Med.
2001;
68
287-297
- 488
Juillerat P, Mottet C, Froehlich F. et al .
Extraintestinal manifestations of Crohn’s disease.
Digestion.
2005;
71
31-36
- 489
Requena L, Requena C.
Erythema nodosum.
Dermatol Online J.
2002;
8
4
- 490
Matis W L, Ellis C N, Griffiths C E. et al .
Treatment of pyoderma gangrenosum with cyclosporine.
Arch Dermatol.
1992;
128
1060-1064
- 491
Jolles S, Niclasse S, Benson E.
Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum.
Br J Dermatol.
1999;
140
564-565
- 492
Brooklyn T N, Dunnill M G, Shetty A. et al .
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind,
placebo controlled trial.
Gut.
2006;
55
505-509
- 493
Mintz R, Feller E R, Bahr R L. et al .
Ocular manifestations of inflammatory bowel disease.
Inflamm Bowel Dis.
2004;
10
135-139
- 494
Berstad A E, Aabakken L, Smith H J. et al .
Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography
in primary sclerosing cholangitis.
Clin Gastroenterol Hepatol.
2006;
4
514-520
- 495
Moff S L, Kamel I R, Eustace J. et al .
Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic
resonance cholangiography and endoscopic retrograde cholangiography.
Gastrointest Endosc.
2006;
64
219-223
- 496
Rosch T, Meining A, Fruhmorgen S. et al .
A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in
biliary strictures.
Gastrointest Endosc.
2002;
55
870-876
- 497
Textor H J, Flacke S, Pauleit D. et al .
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering
in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde
cholangiography.
Endoscopy.
2002;
34
984-990
- 498
Burak K W, Angulo P, Lindor K D.
Is there a role for liver biopsy in primary sclerosing cholangitis?.
Am J Gastroenterol.
2003;
98
1155-1158
- 499
Bergquist A, Ekbom A, Olsson R. et al .
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.
J Hepatol.
2002;
36
321-327
- 500
Broome U, Olsson R, Loof L. et al .
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing
cholangitis.
Gut.
1996;
38
610-615
- 501
Harnois D M, Angulo P, Jorgensen R A. et al .
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Am J Gastroenterol.
2001;
96
1558-1562
- 502
Lee J G, Schutz S M, England R E. et al .
Endoscopic therapy of sclerosing cholangitis.
Hepatology.
1995;
21
661-667
- 503
Mitchell S A, Bansi D S, Hunt N. et al .
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Gastroenterology.
2001;
121
900-907
- 504
Stiehl A, Rudolph G, Kloters-Plachky P. et al .
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis
treated with ursodeoxycholic acid: outcome after endoscopic treatment.
J Hepatol.
2002;
36
151-156
- 505
Stiehl A, Rudolph G, Sauer P. et al .
Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses
in primary sclerosing cholangitis. An 8-year prospective study.
J Hepatol.
1997;
26
560-566
- 506
Stiehl A, Walker S, Stiehl L. et al .
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing
cholangitis. A 3-year pilot study with a placebo-controlled study period.
J Hepatol.
1994;
20
57-64
- 507
Pardi D S, Loftus E V, Kremers W K. et al .
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis
and primary sclerosing cholangitis.
Gastroenterology.
2003;
124
889-893
- 508
Rudolph Jr G, Kloeters-Plachky P, Rost D. et al .
The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time
treatment with ursodeoxycholic acid.
Eur J Gastroenterol Hepatol.
2007;
19
487-491
- 509
Tung B Y, Emond M J, Haggitt R C. et al .
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients
with ulcerative colitis and primary sclerosing cholangitis.
Ann Intern Med.
2001;
134
89-95
- 510
Loftus E V.
Management of extraintestinal manifestations and other complications of inflammatory
bowel disease.
Curr Gastroenterol Rep.
2004;
6
506-513
- 511
Andrews Jr H, Barczak P, Allan R N.
Psychiatric illness in patients with inflammatory bowel disease.
Gut.
1987;
28
1600-1604
- 512
Clouse R E, Alpers D H.
The relationship of psychiatric disorder to gastrointestinal illness.
Annu Rev Med.
1986;
37
283-295
- 513
Drossman D A, Leserman J, Li Z M. et al .
The rating form of IBD patient concerns: a new measure of health status.
Psychosom Med.
1991;
53
701-712
- 514
Guthrie E, Jackson J, Shaffer J. et al .
Psychological disorder and severity of inflammatory bowel disease predict health-related
quality of life in ulcerative colitis and Crohn’s disease.
Am J Gastroenterol.
2002;
97
1994-1999
- 515
Helzer J E, Chammas S, Norland C C. et al .
A study of the association between Crohn’s disease and psychiatric illness.
Gastroenterology.
1984;
86
324-330
- 516
Kurina L M, Goldacre M J, Yeates D. et al .
Depression and anxiety in people with inflammatory bowel disease.
J Epidemiol Community Health.
2001;
55
716-720
- 517
Nordin K, Pahlman L, Larsson K. et al .
Health-related quality of life and psychological distress in a population-based sample
of Swedish patients with inflammatory bowel disease.
Scand J Gastroenterol.
2002;
37
450-457
- 518
Tarter R E, Switala J, Carra J. et al .
Inflammatory bowel disease: psychiatric status of patients before and after disease
onset.
Int J Psychiatry Med.
1987;
17
173-181
- 519
Fuller-Thomson E, Sulman J.
Depression and inflammatory bowel disease: findings from two nationally representative
Canadian surveys.
Inflamm Bowel Dis.
2006;
12
697-707
- 520
Mussell M, Bocker U, Nagel N. et al .
Predictors of disease-related concerns and other aspects of health-related quality
of life in outpatients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol.
2004;
16
1273-1280
- 521
Farrokhyar F, Marshall J K, Easterbrook B. et al .
Functional gastrointestinal disorders and mood disorders in patients with inactive
inflammatory bowel disease: prevalence and impact on health.
Inflamm Bowel Dis.
2006;
12
38-46
- 522
Jones M P, Wessinger S, Crowell M D.
Coping strategies and interpersonal support in patients with irritable bowel syndrome
and inflammatory bowel disease.
Clin Gastroenterol Hepatol.
2006;
4
474-481
- 523
Pace F, Molteni P, Bollani S. et al .
Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control
study of disease impact on quality of life.
Scand J Gastroenterol.
2003;
38
1031-1038
- 524
Addolorato G, Capristo E, Stefanini G F. et al .
Inflammatory bowel disease: a study of the association between anxiety and depression,
physical morbidity, and nutritional status.
Scand J Gastroenterol.
1997;
32
1013-1021
- 525
Bernklev T, Jahnsen J, Schulz T. et al .
Course of disease, drug treatment and health-related quality of life in patients with
inflammatory bowel disease 5 years after initial diagnosis.
Eur J Gastroenterol Hepatol.
2005;
17
1037-1045
- 526
Casellas F, Arenas J I, Baudet J S. et al .
Impairment of health-related quality of life in patients with inflammatory bowel disease:
a Spanish multicenter study.
Inflamm Bowel Dis.
2005;
11
488-496
- 527
Casellas F, Lopez-Vivancos J, Badia X. et al .
Influence of inflammatory bowel disease on different dimensions of quality of life.
Eur J Gastroenterol Hepatol.
2001;
13
567-572
- 528
Cohen R D.
The quality of life in patients with Crohn’s disease.
Aliment Pharmacol Ther.
2002;
16
1603-1609
- 529
Gibson P R, Weston A R, Shann A. et al .
Relationship between disease severity, quality of life and health-care resource use
in a cross-section of Australian patients with Crohn’s disease.
J Gastroenterol Hepatol.
2007;
22
1306-1312
- 530
Porcelli P, Leoci C, Guerra V.
A prospective study of the relationship between disease activity and psychologic distress
in patients with inflammatory bowel disease.
Scand J Gastroenterol.
1996;
31
792-796
- 531
Rubin G P, Hungin A P, Chinn D J. et al .
Quality of life in patients with established inflammatory bowel disease: a UK general
practice survey.
Aliment Pharmacol Ther.
2004;
19
529-535
- 532
Saibeni S, Cortinovis I, Beretta L. et al .
Gender and disease activity influence health-related quality of life in inflammatory
bowel diseases.
Hepatogastroenterology.
2005;
52
509-515
- 533
Li J, Norgard B, Precht D H. et al .
Psychological stress and inflammatory bowel disease: a follow-up study in parents
who lost a child in Denmark.
Am J Gastroenterol.
2004;
99
1129-1133
- 534
Mardini H E, Kip K E, Wilson J W.
Crohn’s disease: a two-year prospective study of the association between psychological
distress and disease activity.
Dig Dis Sci.
2004;
49
492-497
- 535
Mittermaier C, Dejaco C, Waldhoer T. et al .
Impact of depressive mood on relapse in patients with inflammatory bowel disease:
a prospective 18-month follow-up study.
Psychosom Med.
2004;
66
79-84
- 536
Persoons P, Vermeire S, Demyttenaere K. et al .
The impact of major depressive disorder on the short- and long-term outcome of Crohn’s
disease treatment with infliximab.
Aliment Pharmacol Ther.
2005;
22
101-110
- 537
Duffy L C, Zielezny M A, Marshall J R. et al .
Relevance of major stress events as an indicator of disease activity prevalence in
inflammatory bowel disease.
Behav Med.
1991;
17
101-110
- 538
Lerebours E, Gower-Rousseau C, Merle V. et al .
Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based
case-control study.
Am J Gastroenterol.
2007;
102
122-131
- 539
North C S, Alpers D H, Helzer J E. et al .
Do life events or depression exacerbate inflammatory bowel disease? A prospective
study.
Ann Intern Med.
1991;
114
381-386
- 540
Vidal A, Gomez-Gil E, Sans M. et al .
Life events and inflammatory bowel disease relapse: a prospective study of patients
enrolled in remission.
Am J Gastroenterol.
2006;
101
775-781
- 541
Wietersheim von J, Overbeck A, Kiel K. et al .
The significance of recurrence-inducing events for patients with chronic inflammatory
bowel diseases. Results of a prospective longitudinal study over three years.
Psychother Psychosom Med Psychol.
1994;
44
58-64
- 542
Garrett V D, Brantley P J, Jones G N. et al .
The relation between daily stress and Crohn’s disease.
J Behav Med.
1991;
14
87-96
- 543
Greene B R, Blanchard E B, Wan C K.
Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel
disease.
Behav Res Ther.
1994;
32
217-226
- 544
Litcher-Kelly L, Stone A.
Recall and momentary assessments of two self-report items from the Crohn’s Disease
Activity Index (CDAI).
Psychosom Med.
2005;
A-75
1621
- 545
Moser G, Genser D, Tribl B. et al .
Psychological stress and disease activity in ulcerative colitis: a multidimensional
cross-sectional study.
Am J Gastroenterol.
1995;
90
1904
- 546
Gomez-Gil E, Vidal A, Panes J. et al .
Relationship between patient’s subjective stress perception and the course of inflammatory
bowel disease.
Gastroenterol Hepatol.
2003;
26
411-416
- 547
Nigro G, Angelini G, Grosso S B. et al .
Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry
and compliance.
J Clin Gastroenterol.
2001;
32
66-68
- 548
Robertson D A, Ray J, Diamond I. et al .
Personality profile and affective state of patients with inflammatory bowel disease.
Gut.
1989;
30
623-626
- 549
Farhadi A, Keshavarzian A, Van de Kar L D. et al .
Heightened responses to stressors in patients with inflammatory bowel disease.
Am J Gastroenterol.
2005;
100
1796-1804
- 550
Bernklev T, Jahnsen J, Henriksen M. et al .
Relationship between sick leave, unemployment, disability, and health-related quality
of life in patients with inflammatory bowel disease.
Inflamm Bowel Dis.
2006;
12
402-412
- 551
Drossman D A, Leserman J, Mitchell C M. et al .
Health status and health care use in persons with inflammatory bowel disease. A national
sample.
Dig Dis Sci.
1991;
36
1746-1755
- 552
Deter H C, Keller W, Wietersheim von J. et al .
Psychological treatment may reduce the need for healthcare in patients with Crohn’s
disease.
Inflamm Bowel Dis.
2007;
13
745-752
- 553
Timmer A, Bauer A, Dignass A. et al .
Sexual function in persons with inflammatory bowel disease: a survey with matched
controls.
Clin Gastroenterol Hepatol.
2007;
5
87-94
- 554
Timmer A, Bauer A, Kemptner D. et al .
Determinants of male sexual function in inflammatory bowel disease: a survey-based
cross-sectional analysis in 280 men.
Inflamm Bowel Dis.
2007;
13
1236-1243
- 555
De Boer M, Grootenhuis M, Derkx B. et al .
Health-related quality of life and psychosocial functioning of adolescents with inflammatory
bowel disease.
Inflamm Bowel Dis.
2005;
11
400-406
- 556
Sewitch M J, Abrahamowicz M, Bitton A. et al .
Psychosocial correlates of patient-physician discordance in inflammatory bowel disease.
Am J Gastroenterol.
2002;
97
2174-2183
- 557
Wietersheim von J, Jantschek G, Sommer W. et al .
Education of patients with inflammatory bowel diseases.
Wien Med Wochenschr.
1999;
149
352-354
- 558
Moser G, Tillinger W, Sachs G. et al .
Disease-related worries and concerns: a study on out-patients with inflammatory bowel
disease.
Eur J Gastroenterol Hepatol.
1995;
7
853-858
- 559
Kennedy A, Nelson E, Reeves D. et al .
A randomised controlled trial to assess the impact of a package comprising a patient-orientated,
evidence-based self-help guidebook and patient-centred consultations on disease management
and satisfaction in inflammatory bowel disease.
Health Technol Assess.
2003;
7
iii, 1-113
- 560
Kennedy A P, Nelson E, Reeves D. et al .
A randomised controlled trial to assess the effectiveness and cost of a patient orientated
self management approach to chronic inflammatory bowel disease.
Gut.
2004;
53
1639-1645
- 561
Borgaonkar M R, Townson G, Donnelly M. et al .
Providing disease-related information worsens health-related quality of life in inflammatory
bowel disease.
Inflamm Bowel Dis.
2002;
8
264-269
- 562
Lange A, Haslbeck E, Andus T. et al .
Ambulatory education of patient with Crohn disease/ulcerative colitis.
Z Gastroenterol.
1996;
34
411-415
- 563
Larsson K, Sundberg Hjelm M, Karlbom U. et al .
A group-based patient education programme for high-anxiety patients with Crohn disease
or ulcerative colitis.
Scand J Gastroenterol.
2003;
38
763-769
- 564
Bregenzer N, Lange A, Furst A. et al .
Patient education in inflammatory bowel disease does not influence patients knowledge
and long-term psychosocial well-being.
Z Gastroenterol.
2005;
43
367-371
- 565
Irvine E J, Zhou Q, Thompson A K.
The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for
community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian
Crohn’s Relapse Prevention Trial.
Am J Gastroenterol.
1996;
91
1571-1578
- 566
Janke K, Steder-Neukamm U, Bauer M.
Quality of life assessment in Inflammatory Bowel Disease (IBD): German version of
the Inflammatory Bowel Disease Questionnaire (IBDQ-D; disease specific intrument for
quality of life assessment) – first application and comparison with international
investigations.
Gesundheitswesen.
2005;
67
656-664
- 567
Janke K H, Klump B, Steder-Neukamm U. et al .
Validation of the German version of the Inflammatory Bowel Disease Questionnaire (Competence
Network IBD, IBDQ-D).
Psychother Psychosom Med Psychol.
2006;
56
291-298
- 568
Rose M, Fliege H, Hildebrandt M. et al .
Validation of the new German translation version of the „Short Inflammatory Bowel
Disease Questionnaire” (SIBDQ).
Z Gastroenterol.
2000;
38
277-286
- 569
Stjernman H, Granno C, Jarnerot G. et al .
Short health scale: A valid, reliable, and responsive instrument for subjective health
assessment in Crohn’s disease.
Inflamm Bowel Dis.
2008;
14
47-52
- 570
Boer A G, Sprangers M A, Bartelsman J F. et al .
Predictors of health care utilization in patients with inflammatory bowel disease:
a longitudinal study.
Eur J Gastroenterol Hepatol.
1998;
10
783-789
- 571
Miehsler de W, Weichselberger M, Offerlbauer-Ernst A. et al .
Assessing the demand for psychological care in chronic diseases: development and validation
of a questionnaire based on the example of inflammatory bowel disease.
Inflamm Bowel Dis.
2004;
10
637-645
- 572
Miehsler W, Dejaco C, Moser G.
Factor analysis of ADAPT questionnaire for assessment of subjective need for psychological
interventions.
Inflamm Bowel Dis.
2008;
14
142-143
- 573
Kunzendorf S, Jantschek G, Straubinger K. et al .
The Luebeck interview for psychosocial screening in patients with inflammatory bowel
disease.
Inflamm Bowel Dis.
2007;
13
33-41
- 574
Sewitch M J, Abrahamowicz M, Bitton A. et al .
Psychological distress, social support, and disease activity in patients with inflammatory
bowel disease.
Am J Gastroenterol.
2001;
96
1470-1479
- 575
Caprilli R, Gassull M A, Escher J C. et al .
European evidence based consensus on the diagnosis and management of Crohn’s disease:
special situations.
Gut.
2006;
55 Suppl 1
i36-58
- 576
Stange E F, Schreiber S, Folsch U R. et al .
Diagnostics and treatment of Crohn’s disease – results of an evidence-based consensus
conference of the German Society for Digestive and Metabolic Diseases.
Z Gastroenterol.
2003;
41
19-20
- 577
Casellas F, Fontanet G, Borruel N. et al .
The opinion of patients with inflammatory bowel disease on healthcare received.
Rev Esp Enferm Dig.
2004;
96
174-184
- 578
Leshem R N.
Inflammatory bowel disease support groups: a primer for gastroenterology nurses.
Gastroenterol Nurs.
2003;
26
246-250
- 579
Luttenberger H.
The German Crohn Disease/Ulcerative Colitis Society: experiences in the self-help
group.
Z Gastroenterol.
1996;
34 Suppl 2
64-65
- 580
Moody G A, Bhakta P, Mayberry J F.
Disinterest in local self-help groups amongst patients with inflammatory bowel disease
in Leicester.
Int J Colorectal Dis.
1993;
8
181-183
- 581
Joachim G.
The birth and dissolution of an inflammatory bowel disease support group: lessons
in providing support.
Gastroenterol Nurs.
1998;
21
119-124
- 582
Shepanski M A, Hurd L B, Culton K. et al .
Health-related quality of life improves in children and adolescents with inflammatory
bowel disease after attending a camp sponsored by the Crohn’s and Colitis Foundation
of America.
Inflamm Bowel Dis.
2005;
11
164-170
- 583
Takacs L F, Kollman C E.
An inflammatory bowel disease support group for teens and their parents.
Gastroenterol Nurs.
1994;
17
11-13
- 584
Oliveira S, Zaltman C, Elia C. et al .
Quality-of-life measurement in patients with inflammatory bowel disease receiving
social support.
Inflamm Bowel Dis.
2007;
13
470-474
- 585
Milne B, Joachim G, Niedhardt J.
A stress management programme for inflammatory bowel disease patients.
J Adv Nurs.
1986;
11
561-567
- 586
Mussell M, Bocker U, Nagel N. et al .
Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural
treatment: exploratory study of effectiveness.
Scand J Gastroenterol.
2003;
38
755-762
- 587
Schwarz S P, Blanchard E B.
Evaluation of a psychological treatment for inflammatory bowel disease.
Behav Res Ther.
1991;
29
167-177
- 588
Szigethy E, Kenney E, Carpenter J. et al .
Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal
depression.
J Am Acad Child Adolesc Psychiatry.
2007;
46
1290-1298
- 589
Jantschek G, Zeitz M, Pritsch M. et al .
Effect of psychotherapy on the course of Crohn’s disease. Results of the German prospective
multicenter psychotherapy treatment study on Crohn’s disease. German Study Group on
Psychosocial Intervention in Crohn’s Disease.
Scand J Gastroenterol.
1998;
33
1289-1296
- 590
Keller W, Pritsch M, Von Wietersheim J. et al .
Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn’s
disease: main results of the German Prospective Multicenter Psychotherapy Treatment
study on Crohn’s Disease.
J Psychosom Res.
2004;
56
687-696
- 591
Maunder R G, Esplen M J.
Supportive-expressive group psychotherapy for persons with inflammatory bowel disease.
Can J Psychiatry.
2001;
46
622-626
- 592
Wietersheim von J, Kessler H.
Psychotherapy with chronic inflammatory bowel disease patients: a review.
Inflamm Bowel Dis.
2006;
12
1175-1184
- 593
Garcia-Vega E, Fernandez-Rodriguez C.
A stress management programme for Crohn’s disease.
Behav Res Ther.
2004;
42
367-383
- 594
Mickoka-Wallus A, Turnbull D, Moulding N. et al .
Antidepressants and inflammatory bowel disease: a systematic review.
Clin Pract Epidemiol Ment Health.
2006;
2
24-32
- 595
Hilsden R J, Hodgins D C, Timmer A. et al .
Helping patients with Crohn’s disease quit smoking.
Am J Gastroenterol.
2000;
95
352-358
- 596
Hilsden R J, Hodgins D, Czechowsky D. et al .
Attitudes toward smoking and smoking behaviors of patients with Crohn’s disease.
Am J Gastroenterol.
2001;
96
1849-1853
- 597
Cosnes J, Beaugerie L, Carbonnel F. et al .
Smoking cessation and the course of Crohn’s disease: an intervention study.
Gastroenterology.
2001;
120
1093-1099
- 598
Johnson G J, Cosnes J, Mansfield J C.
Review article: smoking cessation as primary therapy to modify the course of Crohn’s
disease.
Aliment Pharmacol Ther.
2005;
21
921-931
- 599
Lancaster T, Stead L.
Physician advice for smoking cessation.
Cochrane Database Syst Rev.
2004;
CD000165
- 600
Lancaster T, Stead L F.
Individual behavioural counselling for smoking cessation.
Cochrane Database Syst Rev.
2005;
CD001292
- 601
Gailhoustet L, Goulet O, Cachin N. et al .
Study of psychological repercussions of 2 modes of treatment of adolescents with Crohn’s
disease.
Arch Pediatr.
2002;
9
110-116
- 602
Engstrom I.
Parental distress and social interaction in families with children with inflammatory
bowel disease.
J Am Acad Child Adolesc Psychiatry.
1991;
30
904-912
- 603
Day A S, Whitten K E, Bohane T D.
Childhood inflammatory bowel disease: parental concerns and expectations.
World J Gastroenterol.
2005;
11
1028-1031
- 604
Engstrom I.
Family interaction and locus of control in children and adolescents with inflammatory
bowel disease.
J Am Acad Child Adolesc Psychiatry.
1991;
30
913-920
- 605
Mackner L M, Crandall W V.
Long-term psychosocial outcomes reported by children and adolescents with inflammatory
bowel disease.
Am J Gastroenterol.
2005;
100
1386-1392
- 606
Mackner L M, Crandall W V, Szigethy E M.
Psychosocial functioning in pediatric inflammatory bowel disease.
Inflamm Bowel Dis.
2006;
12
239-244
- 607
Gold N, Issenman R, Roberts J. et al .
Well-adjusted children: an alternate view of children with inflammatory bowel disease
and functional gastrointestinal complaints.
Inflamm Bowel Dis.
2000;
6
1-7
- 608
Mackner L M, Crandall W V.
Oral medication adherence in pediatric inflammatory bowel disease.
Inflamm Bowel Dis.
2005;
11
1006-1012
- 609
Szigethy E, Levy-Warren A, Whitton S. et al .
Depressive symptoms and inflammatory bowel disease in children and adolescents: a
cross-sectional study.
J Pediatr Gastroenterol Nutr.
2004;
39
395-403
- 610
Zaag-Loonen H J, Grootenhuis M A, Last B F. et al .
Coping strategies and quality of life of adolescents with inflammatory bowel disease.
Qual Life Res.
2004;
13
1011-1019
- 611
Hilsden R J, Meddings J B, Verhoef M J.
Complementary and alternative medicine use by patients with inflammatory bowel disease:
An Internet survey.
Can J Gastroenterol.
1999;
13
327-332
- 612
Hilsden R J, Scott C M, Verhoef M J.
Complementary medicine use by patients with inflammatory bowel disease.
Am J Gastroenterol.
1998;
93
697-701
- 613
Hilsden R J, Verhoef M J, Best van der A. et al .
Complementary and alternative medicine use by Canadian patients with inflammatory
bowel disease: results from a national survey.
Am J Gastroenterol.
2003;
98
1563-1568
- 614
Langhorst J, Anthonisen I, Steder-Neukamm U. et al .
Einsatz komplementärmedizinischer Therapieverfahren bei Patienten mit chronisch entzündlichen
Darmerkrankungen in Deutschland.
Z Gastroenterologie.
2002;
8
641
- 615
Langhorst J, Anthonisen I B, Steder-Neukamm U. et al .
Amount of systemic steroid medication is a strong predictor for the use of complementary
and alternative medicine in patients with inflammatory bowel disease: results from
a German national survey.
Inflamm Bowel Dis.
2005;
11
287-295
- 616
Langmead L, Chitnis M, Rampton D S.
Use of complementary therapies by patients with IBD may indicate psychosocial distress.
Inflamm Bowel Dis.
2002;
8
174-179
- 617
Moser G, Tillinger W, Sachs G. et al .
Relationship between the use of unconventional therapies and disease-related concerns:
a study of patients with inflammatory bowel disease.
J Psychosom Res.
1996;
40
503-509
- 618
Hilsden R J, Verhoef M J.
Complementary and alternative medicine: evaluating its effectiveness in inflammatory
bowel disease.
Inflamm Bowel Dis.
1998;
4
318-323
- 619
Groenewold M, Bücker B, Kohlhammer Y. et al .
Costs, quality of life and health behaviour in CAM: results of a telephone survey
of 1001 adults in Germany.
Focus on alternative and complementary Therapies.
2005;
10
22
- 620
Markowitz J E, Mamula P, delRosario J F. et al .
Patterns of complementary and alternative medicine use in a population of pediatric
patients with inflammatory bowel disease.
Inflamm Bowel Dis.
2004;
10
599-605
- 621 World Health Organisation .WHO Guidelines on developing consumer information on
proper use of traditional, complementary and alternative medicine. World Health Organization
2004
- 622 Bücker B. Alternative Verfahren in der Medizin; Muster der Inanspruchnahme bei
Lübecker Erwachsenen und Kindern. Inauguraldissertation zur Erlangung der Doktorwürde
an der Universitüt Lübeck 2006 1.116
- 623
Matthes H.
Complementary therapies.
Z Gastroenterol.
2003;
41
52-53
- 624 Matthes H. Alternative Therapien bei CED. Hoffmann Jr C, Klump B, Kroesen A Sas
CED-Manual Stuttgart; Thieme 2003: 199-203
- 625 Pschyrembel Klinisches Wörterbuch. Berlin, New York; de Gruyter 2004 260 Aufl
- 626 Linde K, Melchert D. Komplementärmedizin in der Cochrane Collaboration – Chancen
und Risiken. Hornung J Forschungsmethoden in der Komplementärmedizin Über die Notwendigkeit
eine methodologischen Erneuerung Schattauer 1996: 225
- 627
Moher D, Schulz K F, Altman D.
The CONSORT statement: revised recommendations for improving the quality of reports
of parallel-group randomized trials.
Jama.
2001;
285
1987-1991
- 628
Benson K, Hartz A J.
A comparison of observational studies and randomized, controlled trials.
N Engl J Med.
2000;
342
1878-1886
- 629
Concato J, Shah N, Horwitz R I.
Randomized, controlled trials, observational studies, and the hierarchy of research
designs.
N Engl J Med.
2000;
342
1887-1892
- 630
Joos S, Rosemann T, Szecsenyi J. et al .
Use of complementary and alternative medicine in Germany – a survey of patients with
inflammatory bowel disease.
BMC Complement Altern Med.
2006;
6
19
- 631
Kong S C, Hurlstone D P, Pocock C Y. et al .
The Incidence of self-prescribed oral complementary and alternative medicine use by
patients with gastrointestinal diseases.
J Clin Gastroenterol.
2005;
39
138-141
- 632
Langmead L, Rampton D S.
Review article: complementary and alternative therapies for inflammatory bowel disease.
Aliment Pharmacol Ther.
2006;
23
341-349
- 633
Day A S, Whitten K E, Bohane T D.
Use of complementary and alternative medicines by children and adolescents with inflammatory
bowel disease.
J Paediatr Child Health.
2004;
40
681-684
- 634
Heuschkel R, Afzal N, Wuerth A. et al .
Complementary medicine use in children and young adults with inflammatory bowel disease.
Am J Gastroenterol.
2002;
97
382-388
- 635
McCann L J, Newell S J.
Survey of paediatric complementary and alternative medicine use in health and chronic
illness.
Arch Dis Child.
2006;
91
173-174
- 636
Ausfeld-Hafter B, Hoffmann S, Seibold F. et al .
Status of alternative medicine in Crohn disease and ulcerative colitis patents: a
questionnaire survey.
Forsch Komplementarmed Klass Naturheilkd.
2005;
12
134-138
- 637
Binder V.
Prognosis and quality of life in patients with ulcerative colitis and Crohn’s disease.
Int Disabil Stud.
1988;
10
172-174
- 638
Leong R W, Lawrance I C, Ching J Y. et al .
Knowledge, quality of life, and use of complementary and alternative medicine and
therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients.
Dig Dis Sci.
2004;
49
1672-1676
- 639
Quattropani C, Ausfeld B, Straumann A. et al .
Complementary alternative medicine in patients with inflammatory bowel disease: use
and attitudes.
Scand J Gastroenterol.
2003;
38
277-282
- 640
Joos S, Brinkhaus B, Maluche C. et al .
Acupuncture and moxibustion in the treatment of active Crohn’s disease: a randomized
controlled study.
Digestion.
2004;
69
131-139
- 641
Belluzzi A, Brignola C, Campieri M. et al .
Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease.
N Engl J Med.
1996;
334
1557-1560
- 642
Chawla A, Karl P I, Fisher S E.
Effect of N-3 polyunsaturated fatty acid supplemented diet on neutrophil-mediated
ileal permeability and neutrophil function in the rat.
J Am Coll Nutr.
1995;
14
258-263
- 643
Shoda R, Matsueda K, Yamato S. et al .
Therapeutic efficacy of N-3 polyunsaturated fatty acid in experimental Crohn’s disease.
J Gastroenterol.
1995;
30
98-101
- 644
Yuceyar H, Ozutemiz O, Huseyinov A. et al .
Is administration of n-3 fatty acids by mucosal enema protective against trinitrobenzene-induced
colitis in rats?.
Prostaglandins Leukot Essent Fatty Acids.
1999;
61
339-345
- 645
Nakazawa A, Hibi T.
Is fish oil (n-3 fatty acids) effective for the maintenance of remission in Crohn’s
disease?.
J Gastroenterol.
2000;
35
173-175
- 646
Gerhardt H, Seifert F, Buvari P. et al .
Therapy of active Crohn disease with Boswellia serrata extract H 15.
Z Gastroenterol.
2001;
39
11-17
- 647
Summers R W, Elliott D E, Urban J F. et al .
Trichuris suis therapy in Crohn’s disease.
Gut.
2005;
54
87-90
- 648
Kradin R L, Badizadegan Jr K, Auluck P. et al .
Iatrogenic Trichuris suis infection in a patient with Crohn disease.
Arch Pathol Lab Med.
2006;
130
718-720
- 649
Kruis W, Schutz E, Fric P. et al .
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in
maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
853-858
- 650
Rembacken B J, Snelling A M, Hawkey P M. et al .
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative
colitis: a randomised trial.
Lancet.
1999;
354
635-639
- 651
Rolfe V E, Fortun P J, Hawkey C J. et al .
Probiotics for maintenance of remission in Crohn’s disease.
Cochrane Database Syst Rev.
2006;
CD004826
- 652
Malchow H A.
Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission
of colonic Crohn’s disease?.
J Clin Gastroenterol.
1997;
25
653-658
1 Mitgetragen durch die
1 Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie
1 Deutsche Gesellschaft für Chirurgie
1 Deutsche Gesellschaft für Ernährungsmedizin
1 Deutsche Gesellschaft für Innere Medizin
1 Deutsches Kollegium für Psychosomatische Medizin
1 Deutsche Gesellschaft für Koloproktologie
1 Gesellschaft für Pädiatrische Gastroenterologie und Ernährung
1 Deutsche Gesellschaft für Pathologie.
1 Unter Mitarbeit der Deutschen Morbus Crohn/Colitis ulcerosa Vereinigung – DCCV e.V.
1 Die Leitlinie wurde erarbeitet mit Unterstützung des Leitlinien-Entwicklungsportals
www.leitlinienentwicklung.de, einem gemeinsamen Forschungsprojekt der Charité – Universitätsmedizin und der Telematikplattform
für Medizinische Forschungsnetze (TMF) e. V.
2 Koordinationskommitee.
3 Beide Autoren trugen gleichwertig zu dieser Arbeit bei.
Priv.-Doz. Dr. J. C. Hoffmann
Medizinische Klinik I mit Schwerpunkt Gastroenterologie, Diabetologie, Rheumatologie
und Onkologie, St. Marienkrankenhaus
Salzburger Str. 15
67067 Ludwigshafen
Phone: ++ 49/6 21/55 01 22 32
Fax: ++ 49/6 21/55 01 27 95
Email: joerg.hoffmann@st-marienkrankenhaus.de